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AAA+ ATPase ATP hydrolase, AAA domain containing 
ACF   Aberrant crypt foci 
ADRM1  Adhesion regulating molecule 1 
Adc17   ATPase dedicated chaperone of 17 kDa 
ADP   Adenosine-5’-diphosphate 
AJCC   American Joint Committee on Cancer 
AKT   Protein kinase B 
ALK   Anaplastic lymphoma receptor tyrosine kinase 
AMER1  APC membrane recruitment protein 1 
APC   Adenomatous polyposis coli gene 
ARID1A  AT-rich interaction domain 1A 
ATM   ATM serine/threonine kinase 
ATP   Adenosine-5’-triphosphate 
Blm10   Bleomycin-sensitive 10 
BAP1   BRCA1 associated Protein-1 
BRAF   V-raf murine sarcoma viral oncogene homolog B1 
CA19-9  Carbohydrate antigen 19-9 
CA125   Carbohydrate antigen 125 
CDK   Cyclin-dependent kinase 
CDK8 Cyclin-dependent kinase 8 
CDKN2A  Cyclin dependent kinase inhibitor 2A 
CEA   Carcinoembryonic antigen 
CIMP   CpG island methylation pathway 
CIN   Chromosomal instability 
CP   Proteasome 20S core particle 
CRC   Colorectal cancer 
CTNNB1  catenin (cadherin-associated protein), beta 1; b-catenin 
DAF   Abnormal dauer formation 
DCC   Deleted In Colorectal Carcinoma 
Ddi1   DNA damage-inducible 1 
DEUBAD  DEUBiquitinase Adaptor  
Dsk2 Ubiquitin-domain containing dual-specificity protein 
kinase 2 
Dss1   Deletion of SUV3 suppressor 
DNA   Deoxyribonucleic acid 
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DUB(s)  Deubiquitinating enzyme(s) 
E1-E3   Polyubiquitinating enzyme 1-3 
Ecm29   Extracellular mutant protein-29 
ECM   Extracellular matrix 
EGFR   Epithelial growth factor receptor 
EMT   Epithelial-to-mesenchymal transition 
ER   Endoplasmic reticulum 
ERK5   Extracellular signal-regulated kinase 5 
FAMM  Familial atypical multiple melanoma and mole syndrome 
FAP   Familiar adenomatous polyposis 
FIGC   Familial intestinal gastric cancer 
FOXO   Forkhead box O 
GAPPS Gastric adenocarcinoma and proximal polyposis of the 
stomach  
GC   Gastric cancer 
GI   Gastrointestinal 
GPC1   Glypican-1 
GRP78  Glucose-regulated protein 78 
HDGC   hereditary diffuse gastric cancer 
HECT   Homologous to E6AP carboxyl-terminus 
HER2   Human epidermal growth factor receptor 2 
HNPCC  Hereditary nonpolyposis colorectal cancer 
HSF2   Heatshockfactor 2 
Hsp70   Heatshock protein 70 
IDP   Intrinsically disordered proteins 
IGF-1   Insulin-like growth factor 1 
IIS   Insulin/IGF-1 signaling’ 
Ikb-a Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor alfa 
IPTG   b-D-1-thiogalactopyranoside 
JAB1   Jun Activation Domain-Binding Protein 1 
JAMM   JAB1/MPN+/MOV34 
KRAS   V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
lncRNA  Long non-coding RNA 
MAP   MYH-associated polyposis 
MAPK1  Mitogen-activated protein kinase 1 
MHC I   Major histocompatibility complex, class I 
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MIN   Microsatellite instability 
miRNA  MicroRNA 
MMR   DNA mismatch repair gene/pathway 
MMRs   DNA mismatch repair proteins 
MODC  Mouse ornithine decarboxylase 
MOV34  Moloney Leukemia Virus-34 Proviral Integration 
MPK1 mitogen-activated protein kinase 1 
MPN+   Mpr1/Pad1 N-terminal 
mRNA   Messenger RNA 
MSS   Microsatellite stable 
MSI   Microsatellite instability 
mTOR   Mechanistic target of Rapamycin 
NFRKB  Nuclear Factor Related To KappaB Binding Protein 
NF-Y   nuclear factor Y 
NLS   Nuclear localization signal 
NRAS   Neuroblastoma Ras viral oncogene homolog 
Nrf1   Nuclear respiratory factor 1 
Nrf2   Nuclear factor (erythroid-derived)-like 2 
NQO1   NAD(P)H quinone dehydrogenase 1 
ODC   Ornithine decarboxylase 
p16   CDKN2A, i.e. Cyclin dependent kinase inhibitor 2A 
p19   CDKN2D, i.e. Cyclin dependent kinase inhibitor 2D 
p21   CDKN1A, i.e. Cyclin dependent kinase inhibitor 1 
p53   TP53, i.e. Tumor protein 53 
PA200   Proteasome activator 200 kDA 
PAC   Proteasome-assembling chaperone 
PBS   Phosphate buffered saline 
PDAC   Pancreatic ductal adenocarcinoma 
PIP   Proteasome-interaction protein 
PI(3)K   Phosphatidylinositol-3-kinase 
PJS   Peutz-Jeghers syndrome 
POMP   Proteasome maturation protein 
PRU   Pleckstrin-like receptor for ubiquitin 
PSME1-4  Proteasome activator subunit 1-4 
PTEN   Phosphatase and tension homolog 
PTMs   Post-translational modifications 
Rad23   Radiation sensitivity abnormal 23 
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RBR   RING-between-RING 
RING   Really interesting new gene 
RNA   Ribonucleic acid 
RNAi   RNA interference 
RP   Proteasome 19S regulatory particle 
Rpn   Regulatory particle non-ATPase 
Rpt   Regulatory particle triple-ATPase 
S5a   26S proteasome non-ATPase regulatory subunit 4 
Sem1   Suppressor of Exocyst Mutations 1 
siRNA   Small interfering RNA 
SKN-1   Skinhead transcription factor 1 
SMAD2  Mothers against decapentaplegic homolog 2 
SMAD4  Mothers against decapentaplegic homolog 4 
SMAD7  Mothers against decapentaplegic homolog 7 
SMURF2  SMAD specific E3 Ubiquitin protein ligase 2 
SPS   Serrated polyposis syndrome 
SNF2   Sucrose NonFermenting 2 
TAP1   Transporter associated with antigen processing 1 
TGF-b   Transforming growth factor beta 
TME   Tumor microenvironment 
TORC1 transducer of regulated cAMP response element-binding 
protein 1 
TP53   Tumor protein 53 
Ub   Ubiquitin 
Ubp6   Ubiquitin carboxyl-terminal hydrolase 6 
UBA   Ubiquitin-associated domain 
UBA1   Ubiquitin like modifier activating enzyme 1 
UBA6   Ubiquitin like modifier activating enzyme 6 
UBD   Ubiquitin binding domain 
UBH-4  Ubiquitin C-terminal hydrolase 4 
UBL   Ubiquitin-like 
UBLCP1  Ubiquitin-like containing CTD phosphatase 1 
UCH   Ubiquitin C-terminal hydrolase 
UCHL1  Ubiquitin carboxyl-terminal hydrolase L1 
UCHL3  Ubiquitin carboxyl-terminal hydrolase L1 
UCHL5  Ubiquitin carboxyl-terminal hydrolase L5 
Uch37   Ubiquitin C-terminal hydrolase 37; UCHL5 
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UIM   Ubiquitin interacting motif 
UPS   Ubiquitin-proteasome system 
UPR   Unfolded protein response 
Usp   Ubiquitin specific peptidase 
USP14   Ubiquitin carboxy-terminal hydrolase-14 
VEGF   Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 






Ubikitiini-proteasomijärjestelmä (UPJ) on tärkeä proteiinien hajotusjärjestelmä, 
joka yhdessä autofagia-lysosomijärjestelmän kanssa ylläpitää solujen 
proteiinitasapainoa. UPJ:n katalyyttinen ydin on proteasomi: monimutkainen 
holoentsyymi, joka koostuu useista alayksiköistä joilla on eri funktioita. UPJ:n 
toiminnan häiriöt liittivät läheisesti eri tauteihin, kuten moniin ikääntymiseen 
liittyviin hermorappeumasairauksiin (esim. Alzheimerin, Parkinsonin ja 
Huntingtonin tauti), ja erilaisisiin syöpiin. UPJ:n merkityksellisyydestä 
huolimatta sen säätelymekanismit tunnetaan kuitenkin edelleen huonosti, etenkin 
in vivo. Proteasomi-inhibiittoreita (esim. Bortezomib) käytetään yleisesti 
syöpähoidoissa (esim. multippelimyeloomassa ja vaippasolulymfoomassa), 
mutta näihin lääkkeisiin liittyvä toksisuus, potentiaalinen resistanssi ja muut 
haitalliset sivuvaikutukset ovat luoneet akuutin tarpeen vaihtoehtoisille UPJ:tä 
sääteleville hoitokohteille. Tämän väitöskirjan tarkoituksena oli löytää ja 
karakterisoida uusia UPJ:n säätelijöitä elävässä, monisoluisessa organismissa, 
käyttäen mallieläimenä Caenorhabditis elegans-sukkulamatoa. Tavoitteena oli 
lisäksi tutkia projektin aikana tunnistetun UCHL5/UBH-4-proteasomisäätelijän 
potentiaalista syöpämarkkeriroolia eri ruoansulatuskanavan alueen syövissä. 
 
Projektin ensimmäisessä osassa osoitettiin, että UCHL5/UBH-4, proteasomiin 
liittyvä deubikitinaasi, eli proteasomisubstraateista ubikitiinia poistava entsyymi, 
säätelee proteasomin aktiivisuutta C. elegans-sukkulamadoilla. uchl5:n 
hiljentäminen (knockdown) lisäsi proteotoksisten proteiinien hajotusta ihmisen 
syöpäsoluissa. Sukkulamadoilla ubh-4-ekspressiota sääteli ikääntymiseen 
liittyvä insuliini/IGF-1 signalointireitti (IIS) kudos-riippuvaisesti DAF-
16/FOXO-transkriptiotekijän kautta. Lisäksi lievä ubh-4:n ekspressiotason lasku 
sai aikaan vähäisen eliniän pidentymisen, vaikuttamatta kuitenkaan 
sukkulamatojen jälkeläismäärään. Projektin toisessa osassa UCHL5:n tuumori-
ekspressiota arvioitiin immunohistokemiallisesti paksusuolensyöpä-, 
mahasyöpä- ja haiman duktaalikarsinooma-potilaiden kasvainnäytteistä. Korkea 
UCHL5-immunoekspressio oli yhteydessä kasvaneen eliniän odotteen kanssa 
potilailla, joilla oli imusolmuke-positiivinen (Dukes C/vaihe III) 
peräsuolensyöpä. Positiivinen nukleaarinen ja korkea sytoplasminen UCHL5-
immunoekspressio liittyivät parempaan ennusteeseen haiman 
duktaalikarsinoomassa. Mahasyövässä positiivinen UCHL5-immunoekspressio 
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korreloi nousseen elinajan ennusteen kanssa niillä potilailla, joilla oli pieni 
kasvainkoko (<5 cm), tai I-II-vaiheen syöpä. 
 
Tässä väitöskirjassa osoitettin, että UCHL5/UBH-4-deubikitinaasi säätelee 
proteasomin toimintaa ja lisäksi UCHL5 on uusi prognostinen syöpämarkkeri, 
jolla on potentiaalisesti kliinistä merkitystä. Tulevaisuudessa UPJ:n tunnustettu 
merkitys eri sairauksien synnyssä ja kehityksessä todennäköisesti vain kasvaa, 







The ubiquitin-proteasome system (UPS) is the major cellular pathway for 
controlled protein degradation, and, together with the autophagy-lysosome 
pathway, it is a central player in maintaining protein homeostasis. The catalytic 
core of the UPS is the proteasome, a complex holoenzyme composed of multiple 
different subunits with varying functions. Disruptions in the UPS are associated 
with many pathological conditions, including aging-related neurological diseases 
(such as Alzheimer’s, Parkinson’s, or Huntington’s disease), as well as different 
cancers. Proteasome inhibitors (e.g. Bortezomib) are in use as cancer therapeutics 
(e.g. in refractory multiple myeloma and mantle cell lymphoma), but dose-
limiting toxicities, drug-resistance and other adverse side-effects have created an 
acute need for identifying alternative targets that modulate the UPS. Yet, despite 
its wide-ranging importance, it remains to be defined how UPS is regulated, 
especially in vivo. The purpose of this thesis was to provide new information on 
UPS modulation in a living, multicellular organism, with the help of the model 
organism Caenorhabditis elegans. Further, the aim was to investigate the 
potential role of an identified proteasome regulator UCHL5/UBH-4 as a 
biomarker in three gastrointestinal cancers: colorectal cancer (CRC), gastric 
cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). 
 
In the first part of the study, it was established that UCHL5/UBH-4, a 
proteasome-associated deubiquitinating enzyme (DUB), modulates proteasome 
activity in C. elegans, and additionally increases the degradation of proteotoxic 
proteins in human cancer cells. In C. elegans, UBH-4 expression was 
demonstrated to be regulated by the ageing-regulating Insulin/IGF-1 signaling 
(IIS) pathway through the transcription factor DAF-16 in a tissue-specific 
manner. Further, minor knockdown of ubh-4 resulted in a short lifespan extension 
without affecting progeny amounts. In the second part of the study, the role of 
UCHL5 was investigated in various gastrointestinal cancers. UCHL5 
tumorexpression was scored with immunohistochemistry from representative 
patient tumor samples in CRC, GC and PDAC. UCHL5-immunoexpression 
correlated with increased survival in the subgroup of patients with lymph node-
positive (Dukes C/stage III) rectal cancer. In addition, both positive nuclear and 
high cytoplasmic UCHL5-immunoexpression associated with better prognosis in 
PDAC. Positive UCHL5-immunoexpression was also linked to enhanced 
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survival in the subgroups of gastric cancer patients with small tumors (<5 cm) or 
stages I-II of the disease. 
 
This thesis identified UCHL5/UBH-4 as a new proteasome modulator, and 
further UCHL5 as a novel prognostic marker with potential clinical relevance. In 
the future, the recognized significance of UPS in the development and progress 
of different diseases is only likely to grow. Therefore, understanding the 







Protein homeostasis, the dynamic process of protein translation and destruction, 
is maintained in part through the ubiquitin-proteasome system (UPS), a 
multifaceted pathway that degrades the majority of all cellular proteins. 
Dysfunctions in this system are present in several age-related diseases, including 
many types of cancer. Globally, gastrointestinal cancers remain a serious issue, 
affecting yearly the lives of millions of people. Despite recent developments in 
their treatment, there is an acute need for more accurate and reliable prognostic 
markers in clinical praxis. The purpose of this thesis was to identify and 
characterize new proteasome regulators in a living, multicellular organism. 
Further, the aim was to investigate the role of one of the identified regulators, the 
proteasome-associated deubiquitinating enzyme UCHL5/UBH-4, in three 
gastrointestinal cancer types: colorectal cancer, gastric cancer and pancreatic 
ductal adenocarcinoma. The literature review will first discuss the specifics of 
the ubiquitin-proteasome system, and its various roles in maintaining cellular 
proteostasis. It will then expand on the three gastrointestinal cancers studied in 
this thesis, and touch on biomarkers available in these cancer types. The results 
section will in turn examine the function of UCHL5/UBH-4 in proteasome 
regulation, and describe the prognostic marker role of human UCHL5 in 





1. The ubiquitin-proteasome system 
 
Proteins are constructed of long polypeptide chains, forming a diverse group of 
important biomolecules. They are at the very core of our existence, from complex 
building blocks to facilitating and carrying out the multitude of processes within 
our cells that define life as we know it. Cellular protein content is thoroughly 
regulated, and complications in protein homeostasis (proteostasis) lead to 
proteotoxicity, different disease conditions, and potentially death. The delicate 
balance in protein turnover is maintained through the synthetization of new 
proteins (translation), as well as through the degradation of misfolded or 
superfluous proteins. The destruction of proteins is performed by two parallel and 
partially overlapping cellular pathways: the autophagy-lysosome pathway (ALP, 
or autophagy) and the ubiquitin-proteasome system (UPS). In autophagy, the 
cytoplasmic components are delivered into lysosomes for degradation, thereby 
clearing out entire organelles and large protein aggregates, in addition to single 
proteins [1,2]. In contrast, UPS is the major pathway for e.g. the degradation of 
irregular or redundant regulatory proteins, thus destroying substrates specifically 
targeted to the UPS [3]. The two degradation systems connect to and complement 
each other in complex and yet to be fully defined ways; for example, UPS 
impairment has been demonstrated to upregulate autophagy in several model 
systems [4-7]. 
 
Briefly, in the UPS, a large constituent of substrates are marked for degradation 
through their polyubiquitination, which is facilitated by three groups of enzymes: 
E1-E3 (enzyme 1-3) [8] . These enzymes are divided into their respective classes 
according to their ubiquitin (Ub) activating, conjugating or ligating capacity. 
Once a polyubiquitinated protein targeted to the proteasome reaches its 
destination, it is sequentially deubiquitinated, unfolded and translocated into the 
proteasome core for destruction. At the heart of the UPS is the proteasome, a 
multisubunit holoenzyme complex that degrades all UPS substrates [9]. 
Additionally, another group of proteins known as deubiquitinating enzymes 
(DUBs) remove polyubiquitin from potential substrates, prior to their 
degradation [10]. Through its active role in protein turnover, UPS takes part 
essentially in all cellular processes, including protein quality control, signal 
transduction, cell-cycle control, DNA repair, transcription and  major 
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histocompatibility complex I (MHC I) antigen presentation, to name but few [11]. 
Aberrant UPS function is present in a wide array of pathological conditions, 
including several aging-related and neurodegenerative diseases (e.g. 
Alzheimer’s, Parkinson’s and Huntington ’s disease), viral infections and many 
types of cancer [12,13]. 
 
The proteasome is present in all eukaryotes, archaea and even some eubacteria 
[11]. At any given time, a large portion of proteasomes are in the nucleus, but 
they are also found throughout the cytosol and adjacent to membraned organelles, 
such as mitochondria [14]. Localization of proteasomes is dynamic: populations 
shift between different cellular compartments, presumably in response to 
fluctuating proteolytic needs [15]. Active proteasomes have also been discovered 
outside cells, e.g. in the serum or cerebrospinal fluid, and the levels of these 




1.1. Proteasome structure and function 
 
The best characterized form of the proteasome consists of a 20S core particle 
(CP), joined at one (26S) or both ends (30S) by a 19S regulatory particle (RP or 
PA700). Eukaryotic proteasomes share generally a high degree of conservation, 
in both subunit composition and genetic sequence [11]. In mammalian cells, more 
than 50% of proteasomes appear to exist as free 20S, and only 20%-30% were 
identified as 26S [22-25]. CPs can form with alternate core subunits, as well as 
hybrid proteasomes, but in this text the term “proteasome” refers to the canonical 
26S proteasome, unless otherwise stated. CP-RP2 (CP with two 19S RPs 
attached) has a molecular weight of roughly 2.5 MDa, and it is composed of over 
50 subunits [26]. Main function(s) of the key subunits are summarized in Table 






Table 1. Key function(s) of the 26S subunits and associated DUBs. 
Subunit(s)  Function 
 Rpn1, Rpn10, Rpn13   Ub receptors 
 Rpn11   detaching last substrate Ub(s) (DUB) 
 USP14, UCHL5/UBH-4 
  detaching substrate Ub (associated DUBs),  
  19S activation 
 Rpt 1-6 AAA+-ATPases   binding, unfolding and translocation of the substrate 
 Rpt2, Rpt3, Rpt5   opening the 20S gate 
 a-subunits (N-termini)   forming 20S gate structure 
 b1, b2, b5   catalytic activity (peptide hydrolysis) 
Table modified from: Collins and Goldberg, 2017. [28] 
 
 
1.1.1. 20S core particle 
 
The 20S core particle is the proteolytic unit of the UPS, degrading the multitude 
of proteasomal substrates that are processed by the system. 20S and 19S structure 
and the relative locations of their various subunits are depictured in Figure 1. 
The 20S core has a molecular weight of approximately 730 kDa [29]. The 
canonical CP consists of four coaxially stacked heteroheptameric rings (two outer 
a-rings, two inner b-rings), forming a barrel-like structure [30]. The seven a-
subunits (a1-a7) are all distinct from one another, but share considerable 
structural similarity [31]. The N-termini of the a-subunits form a 13 Å molecular 
gate that controls substrate access, as well as provides attachment sites for 
proteasome activators, including 19S [32]. The N-terminus of the a3-subunit is 
particularly important for the configuration and opening of the gate, as deletion 
of a3 results in a permanently open pore [32]. The outer-facing surface of the a-
rings form seven binding pockets for the different proteasomal activators, which 
in turn modulate gate opening [33,34]. Many of the 20S a-subunits contain a 
nuclear localization signal (NLS), which is important for determining proteasome 
location in cells [35-37]. The central inner cavity of the 20S contains the actual 
proteolytic functions of the proteasome [38]. Of the seven b-subunits, only three 
have catalytic activity: b1, b2 and b5 [38]. The proteolytic specificity of these 
three subunits are in order: caspase-like (cleavage after acidic residues), trypsin-
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like (cleavage after basic residues), and 
chymotrypsin-like (cleavage after 
hydrophobic residues) activity [38]. 
 
 
1.1.2. 19S/PA700 regulatory particle 
 
Because of its closed architecture, the 20S is 
inherently repressed, and requires activators 
to facilitate gate opening and substrate 
degradation; however, essentially any 
protein that enters the pore can be degraded 
[11]. The most comprehensively 
characterized proteasome activator is the 
canonical 19S RP, which has a molecular 
weight of approximately 930 kDa [39]. 19S 
regulates binding, deubiquitination, 
unfolding and translocation into the core of 
the various proteasomal substrates [9]. The 
19S structure is divided into two 
subcomplexes: the lid and the base [9]. In 
the base subcomplex, six AAA+ ATPase subunits, known as regulatory particle 
subunits 1-6 (Rpt1-Rpt6), form a heterohexameric ring [40]. They are joined by 
four regulatory particle non-ATPase subunits (Rpn1, Rpn2, Rpn10/S5a and 
Rpn13/ADRM1) [40]. The ATPase ring assists in the opening of the 20S gate, 
and diverts energy from ATP hydrolysis into the unwinding and translocation of 
proteasome substrates [33,41-45]. The lid subcomplex is a horseshoe-shaped 
structure, composed of nine different subunits (Rpn3, Rpn5-9, Rpn11, Rpn12 and 
Rpn15/Dss1/Sem1). In addition, there are several proteins that transiently 
associate with the RP, which are not considered de facto stoichiometric subunits, 
e.g. the proteasome-associated DUBs ubiquitin carboxyl-terminal hydrolase L5 
(UCHL5) and ubiquitin carboxy-terminal hydrolase 14 (USP14) (see Table 1) 
[46, 47]. 
 
Of the 19S subunits, Rpn1 [48], Rpn10 [49] and Rpn13 [50] recognize and bind 
ubiquitin. Rpn10 binds ubiquitin through its C-terminal Ub-interacting motifs 
(UIMs) [51], and Rpn13 with its pleckstrin-like receptor for ubiquitin (PRU) 
Figure 1. Proteasome structure. 
Catalytic core subunits marked in 
green. Image modified from 
D’Arcy et al., 2015. [26] 
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domain [52,53]. Rpn10 and Rpn13 bind additionally Ub-like (UBL) domains, but 
their affinity for free ubiquitin is weak [28]. Rpn1 was recently identified as a 
third Ub-receptor on the proteasome [48], with an affinity for UBL-domains 
[54,55]. Though both Rpt5 [56] and Rpn15 [57] bind ubiquitin, it is unknown if 
they function as ubiquitin receptors on the proteasome [9,58]. The roles of the 
different proteasomal Ub-receptors appear to be both distinct and redundant, and 
potentially depend on the substrate in question [28]. Whether the Ub-receptors  
work together, simultaneously, or in sequence, remains to be defined [28]. 
 
1.1.3. Alternate proteasome activators 
 
Three different activator families function in 20S gate opening, providing access 
for proteasomal substrates into the central chamber [11]. The most conserved 
family of proteasome activators are the eukaryotic 19S, archaeal PAN and 
eubacterial ARC/Mpa. The other two families are 11S/PA28/REG/PA26 and 
PA200/Blm1 [11]. These two families share less conservation between species, 
and their functions and biological relevance is not as well-defined as that of 19S 
[11]. The common trait for the alternate activators is that they cannot recognize 
ubiquitin or hydrolyze ATP [59]. Instead, their substrates are small, simple 
proteins, such as cyclin-dependent kinase (CDK) inhibitors p16, p19 and p21 
[60]. The 20S can associate at the same time with either one or two 11S or PA200 
activators, or in combination with 19S and a second activator, creating hybrid 
proteasomes [24]. 
 
Higher eukaryotes have three different 11S-isoforms: PA28a,b,g [61]. PA28a 
(Proteasome activator subunit 1, PSME1) and PA28b (PSME2) assemble into a 
heteroheptamer ring (PA28ab, containing three a and four b subunits), and 
PA28g (PSME3) is a homoheptamer. The role of 11S in cellular functions is not 
well understood [11], but the PA28ab-complex is found for the most part 
associated with the immunoproteasome [62]. PA28g has been connected to the 
degradation of natively unfolded proteins [63-65], and it appears to be of more 
primordial origin than the two other isoforms, as it is expressed throughout the 
metazoan line [66]. Hybrid proteasomes with one 11S and 19S are implicated in 
antigen production for the MHC I complex [24]. PA28ab is also more abundant 
in immune tissues and it is upregulated by interferon-g [67]. Additionally, 11S 




The 200 kDa monomeric PA200/Blm10 (PSME4) has a dome-like shape [69-
71], and it promotes only partial opening of the 20S gate [72]. PA200 is believed 
to promote degradation of peptides, but not full-sized proteins [11]. The activator 
is implicated in a variety of processes, including 20S assembly [73], proteasome 
inhibition [74], DNA repair [69], spermatogenesis [75] and mitochondrial 
checkpoint regulation [72]. PA200 expression is especially abundant in the testis 
[76], either forming hybrid proteasomes (19S-20S-PA200), or as single or 
double-capped complexes (PA200-20S and PA200-20S-PA200) [77]. In 
addition, PA200 deficient male mice have reduced fertility [77], and PA200 is 
critically involved in histone degradation during DNA damage and 
spermatogenesis [77]. 
 
1.1.4. Tissue-specific proteasomes 
 
In mammals, constitutive catalytic b-subunits can be replaced upon induction, or 
tissue-specifically in a variety of immune-related tissues or cells (such as 
monocytes and lymphocytes) by alternative b1i, b2i, b5i and/or b5t subunits (“i” 
for immunoproteasome, “t” for thymoproteasome) [78,79]. The bi-subunits of 
the immunoproteasome demonstrate altered specificity toward cleaving after 
basic and hydrophobic residues, which is presumed to increase the affinity of the 
degradation products to the MHC I complex molecules [80]. The 
immunoproteasome has also been suggested to show a preferential association 
with the PA28ab activator [81]. The 26S holoenzyme can contain both 
constitutive and immune b-subunits simultaneously [79]. Upon viral, bacterial, 
or fungal infections, up to 90% of constitutive proteasomes in relevant tissues 
can be replaced by immunoproteasomes [82-84], suggesting that the 
immunoproteasome can also perform vital housekeeping functions normally 
governed by constitutive proteasomes [82]. 
 
The thymoproteasome has been found only in the cortical epithelial cells of the 
thymus, shown to play a central role in the maturation of CD8+ T-cells [30]. The 
catalytic subunits of the thymoproteasome are b1i, b2i and b5t, and the 
chymotrypsin-like activity of b5t subunit is lower than that of either b5 or b5i 
[40,79]. The third known tissue-specific proteasome is the spermatoproteasome. 
In Drosophila, two alternate a-subunits (a4T1 and a4T2) are expressed only in 
the male germline from mid to late stages in spermatogenesis [85-87]. 
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Interestingly, additional 12 proteasome subunits have been found to exist as 
multiple isoforms in Drosophila, with all of the non-canonical isoforms 
expressed exclusively in the testes (reviewed in [88]). Mammalian testes also 
have an alternate core subunit, a4s/PSMA8, which is only expressed in 
spermatids and mature sperm [77,89] in a same complex with 
immunoproteasome specific b-subunits [77,90]. This demonstrates that by 
switching a few subunit(s), proteasome function and specificity can be greatly 
altered, reflecting the dynamic plasticity inherent in the complex. 
 
 
1.2. Polyubiquitinating enzymes 
 
Ubiquitin, the ubiquitous biomolecule used to tag proteasomal substrates, is a 
small, 76-aminoacid protein [91,92]. UPS target protein polyubiquitination is a 
stepwise process facilitated by three classes of enzymes: E1-E3. An additional 
group of E4 enzymes is also sometimes described; E3s that extend and modify 
existing ubiquitin chains [93,94]. The polyubiquitination cascade is illustrated in 
Figure 2. To start the process, ubiquitin is activated by an ATP-dependent E1 
ubiquitin activator. Of the eight human E1 enzymes, two are associated with the 
UPS: UBA1 and UBA6 (reviewed in [95]). UBA6 is a fairly recent discovery, 
described as an ubiquitin activator as late as 2007 [96,97]. Next, one of several 
dozen human E2s acts as ubiquitin conjugator. In the third group of ubiquitin 
ligases are approximately 600 different E3s, which confer substrate specificity in 
the system [98]. Substrate bound E3s recruit Ub-loaded E2s, and facilitate or 
directly catalyze the transfer of Ub to a target substrate [98]. E3s are divided into 
three families: homologous to E6AP carboxyl-terminus (HECT) E3 ligases, 
really interesting new gene (RING) E3 ligases and RING Between RING (RBR) 
E3 ligases [99]. The RING E3s are the largest family, and they promote 
approximately 20% of Ub-mediated degradation [100,101]. Together with the 
RBR E3s, RING E3s use E2 enzymatic activity to transfer the Ub directly to the 
substrate by acting as a scaffold [98,99]. In contrast, the few dozen HECT E3 
ligases catalyze Ub transfer to the substrate independently of E2 enzymatic 




Figure 2. The polyubiquitination process of proteasome substrates. Ubiquitin (Ub, 
red circles) is activated by E1 (Ub-activating enzyme), requiring ATP hydrolysis. 
Activated Ub is transferred to an E2 (Ub-conjugating enzyme), and then directly to a 
substrate (in blue) associated with an E3 RING ligase, acting as a scaffold. Alternatively, 
Ub can be transferred to an E3 HECT ligase, forming an E3-Ub intermediate, followed 
by substrate ubiquitination. Deubiquitinating enzymes (DUBs, in green) can remove 
ubiquitin at multiple steps throughout the process. Components are not in scale. 
Modified from Lip et al., 2017. [99] 
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Protein ubiquitination status can direct proteins to multiple fates, e.g. serving as 
subcellular localization signals, or degradation tags for both autophagy and UPS 
[105-109]. Ubiquitination is divided into monoubiquitination, multimono-
ubiquitination (attachment of several single ubiquitin moieties into the same 
molecule), and polyubiquitination [39,108,110-114]. Ubiquitin can form eight 
different kinds of linkages with itself: either through its seven lysine (K) residues 
(K6, K11, K27, K29, K33, K48, K63), or its N-terminus [115]. The chains can 
be homotypic, or contain different linkages (heterotypic), and all assembly forms 
are potential intracellular targeting signals [115]. Forked chains forming on 
adjacent lysines of a donor ubiquitin are not recognized by the proteasome [116]. 
The formation of these undegradable chains can be prevented to some degree by 
cytosolic ubiquitin interacting motif (UIM) proteins, such as Rpn10 [116]. The 
canonical signal for proteasomal degradation is a 4-6 moieties long Ub-chain, 
containing K11 or K48 linkages [92]. K48-linked polyubiquitin chains are also 
the most abundant ubiquitin tags in cells [117,118]. Additionally, K6-, K27-, 
K29- and K33-linked polyubiquitin chains can be targeted for proteasomal 
degradation, although this is not always the case [118]. Ubiquitination on 
residues other than lysine (cysteine, serine, threonine) [119] or multiple 
monoubiquitination or diubiquitination may also target substrates to the 
proteasome [120,121]. Different cellular compartments contain variable pools of 
E3s and DUBs, which further contributes to make the ubiquitination status of a 
specific substrate highly context specific [122]. 
 
 
1.3. Deubiquitinating enzymes 
 
Polyubiquitination and even association with the proteasome does not guarantee 
substrate degradation [123,124]. In a complete or partial reversal of the process 
mediated by polyubiquitinating enzymes, deubiquitinases remove ubiquitin from 
target proteins [124]. The human genome codes for approximately 90 Ub-specific 
DUBs [125-128]. These enzymes cleave the isopeptide bond between the 
substrate and the primary ubiquitin, detaching the whole chain simultaneously, 
or an isopeptide bond located between different Ub-molecules in a chain, causing 
chain trimming [26,122]. Some DUBs display linkage specificity (e.g. K48, 
K63), while others cleave multiple chain types [129]. Several DUBs only become 
active once they have been recruited to their target location, or bound to a 
substrate [122]. An integral part of a DUB is its Ub-binding domain (UBD), 
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consisting of a ubiquitin-interacting motif (UIM), a zinc finger Ub-specific 
protease domain (ZnF-UBP) [125] and Ub-associated domain (UBA) [130]. 
Substrate specificity is thought to be conveyed through the Znf-UBP domain 
[125]. 
 
Based on sequence similarity and conservation in their domains, DUBs are 
divided into six families [131]. These are the JAB1/MPN/MOV34-family 
(JAMMs), motif-interacting with ubiquitin-containing novel DUB family 
(MINDYs), Machado–Josephin domain-containing proteases (MJDs), ovarian 
tumour proteases (OTUs), ubiquitin carboxy-terminal hydrolases (UCHs) and 
ubiquitin-specific proteases (USPs) [132]. Five of these families are thiol 
proteases, or cysteine peptidases, whereas JAMMs are a family of zinc 
metalloproteases [122,131,133]. UCHs all have a N-terminal catalytic domain, 
and some of them also contain additional C-terminal domains that facilitate 
protein-protein interactions [127]. The four human UCHs are UCHL1, UCHL3, 
UCHL5/Uch37 and BRCA1 associated Protein-1 (BAP1) [122]. The USP family 
has approximately 60 human members, including the proteasome-associated 
USP14/Ubp6 [128]. For JAMMs, catalytic activity is conveyed by their JAMM-
domain, and members include the proteasome subunit Rpn11 [134,135]. DUBs 
participate in regulatory cellular processes in many ways. They display variable 
cellular localization, and can change substrate ubiquitination by directly 
interacting with E3s [136]. They also act at the proteasome to either hinder or 
promote degradation of polyubiquitinated substrates [122,136]. One of their 
fundamental roles is the co-translational processing of pro-ubiquitin: most 
organisms express ubiquitin as a linear polymer of multiple ubiquitin copies, 




1.4. Proteasome-mediated protein degradation 
 
An estimated 80% of proteins in mammalian cells are degraded by the 
proteasome, including misfolded or superfluous proteins, in addition to the bulk 
of recycled housekeeping proteins [139]. Approximately 90% of proteasomal 
degradation products are 2-10 residues in length [140]. Though the majority of 
these are further degraded into free amino acids in the cytosol to be reused in the 
translation of new proteins [13,141,142], some are repurposed in higher 
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vertebrates by the Transporter associated with antigen processing 1 (TAP1) 
protein to be loaded onto the MHC I complexes as precursors of antigenic 
peptides [143]. Proteasome function is flexible, and partial degradation may also 
result in protein activation (e.g. p100 in the NF-kb pathway) [144]. Moreover, 
not all proteasome substrates arrive to the 20S through the polyubiquitination 
process [145,146]. Two pathways of protein hydrolysis exist at the proteasome: 
ubiquitin-dependent and ubiquitin-independent degradation. These two 
processes are not mutually exclusive, and different populations of the same 
substrate may be degraded by either process, often depending on the level of 
substrate unfolding prior to degradation [147]. 
 
1.4.1. Ubiquitin-independent protein degradation 
 
Best characterized among proteasome substrates that are degraded ubiquitin-
independently is ornithine decarboxylase (ODC), one of the crucial enzymes 
involved in polyamine biosynthesis [148,149]. In addition, partially or 
completely unfolded proteins, as well as native proteins containing extensive 
unstructured elements (longer than 30 aminoacid residues) are substrates of the 
free 20S CP [150-152]. To this latter group belong especially key regulatory and 
signaling molecules that are important to many cellular processes [153]. 
Intrinsically unstructured regions are found in up to 44% of human protein coding 
genes, making them potential substrates of the 20S [150]. Not much is yet known 
about the regulation of this pathway, although two proteins, NAD(P)H quinone 
dehydrogenase 1 (NQO1) [147,154] and protein deglycase DJ-1 [155], have been 
implicated in 20S regulation upon oxidative stress [155]. The Ub-independent 
pathway appears to be a critical part of proteostasis control, especially upon 
oxidative stress, whereas under basal conditions 26S-mediated degradation 
probably constitutes the majority of proteasomal degradation [156]. A majority 
of proteins that are degraded through the Ub-independent pathway belong to the 
intrinsically disordered proteins (IDPs) family [157]. Ub-independent 
degradation is an important complementary pathway to the Ub-dependent 
degradation, critical for the removal of damaged and unfolded proteins [145]. 
 
1.4.2. Ubiquitin-dependent protein degradation 
 
19S goes through at least four (s1-s4) conformational states [158] during the 
degradation sequence, reflecting the functional cycle of the proteasome [159]. 
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Substrate degradation consists of the following: 1) initial reversible ATP-
activated binding (with Rpn1, Rpn10, Rpn13) [50,160,161]; 2) committing to 
degradation, which requires an unfolded domain on the substrate and ATP 
hydrolysis [160]; 3) substrate deubiquitination by Rpn11 (and/or USP14 and 
UCHL5) [123]; 4) unfolding of the substrate, and its translocation into the CP 
core for degradation [34,162,163]. It is still somewhat ambiguous what 
constitutes an appropriate unfolded region to promote effective proteasomal 
degradation. Research suggests that the region should display minimum 
flexibility, and contain at least 30 amino acids of varying identity with a bias 
towards hydrophobic residues [164,165]. Sequences of high repetition show 
resistance to proteasomal degradation [166], and accumulation of that kind of 
proteins is linked to many proteotoxic diseases, e.g. Alzheimer’s or Parkinson’s 
disease [167,168]. The location of the unfolded region in relation to the 
placement of the Ub-tag(s) potentially influences the importance of the region in 
ultimately deciding substrate fate [28]. 
 
While a protein resides on the proteasome, other competing processes may affect 
its fate. For example, proteasome-associated DUBs can rescue substrates from 
degradation after their initial binding to the proteasome [169]. Once a substrate 
is deubiquitinated, it no longer has a tether at the proteasome, and may escape 
degradation altogether [15]. To prevent this, the DUB-activity of Rpn11 is 
coupled to ATP hydrolysis [135], and it acts late in the catalytic cycle, after 
ATPase engagement, and proper alignment of the substrate for entry into the core 
[170-173]. The 19S endogenous ubiquitin receptors and proteasome-bound 
shuttling factors, which include DNA damage-inducible 1 (Ddi1), ubiquitin-
domain containing dual-specificity protein kinase 2 (Dsk2) and radiation 
sensitivity abnormal 23 (Rad23), presumably facilitate testing out different 
conformations of the substrate, until it is favorably aligned for translocation into 
the core [15]. 
 
 
1.5. Proteasome modulation 
 
Conventionally, the proteasome has been understood to be a static machine that 
faithfully degrades substrates from the moment it is assembled until it is 
ultimately destroyed, with little variation in its function or activity. Conversely, 
many studies in recent years have demonstrated that the UPS and the proteasome 
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in particular are regulated in various ways, from orchestrated changes in overall 
proteasome abundance, proteasome assembly (or disassembly) rate, post-
translational modifications (PTMs) of different subunits, to changes in 
proteasome location and recruitment [9]. 
 
1.5.1. Transcriptional regulation 
 
Modulating proteasome abundance through transcriptional events is a significant 
mechanism regulating the UPS. Following proteasome inhibition or proteotoxic 
stress, proteasome amounts are quickly increased, requiring the operation of 
master regulators of proteasome transcription [15]. Two of these, transducer of 
regulated cAMP response element-binding protein 1 (TORC1) and Extracellular-
Signal-Regulated Kinase 5 (ERK5)/mitogen-activated protein kinase 1 (MPK1) 
are especially important for this process [174]. These two maintain proteasome 
homeostasis, by reversibly promoting the expression of proteasome subunits and 
RP assembly chaperones in response to acute stress [174]. On a more general 
level, proteasome subunit expression is regulated by several transcription factors, 
including nuclear factor Y (NF-Y), nuclear respiratory factor 1 and 2 (Nrf1 and 
Nrf2) and their C. elegans orthologue skinhead transcription factor 1 (SKN-1), 
Heatshock factor 2 (HSF2), Rpn4 (in yeast), and abnormal dauer formation 
16/forkhead box O (DAF-16/FOXO) [60,175,176]. Subsequently, almost all 
proteasome subunit promoters have binding sites for these transcription factors, 
and multiple binding sites for FOXO [60]. They work separately and in concert, 
along with various other effectors in modulating subunit expression, both 
following stress and under basal conditions (reviewed extensively in [60]). For 
example, in yeast stress induces Rpn4 regulated subunit transcription and the 
expression of proteasome assembly chaperones [175,176]. These transcription 
factors are also themselves proteasomal substrates, thus forming negative 
feedback loops with the proteasome [177]. 
 
1.5.2. Proteasome assembly and disassembly 
 
The multifaceted proteasome assembly is steered by both intrinsic structural 
features of the subunits, as well as by dedicated assembly factors [178]. The 
proteasome is constructed in several parallel and successive steps into a 
catalytically active complex, facilitated by specific chaperones and maturation 
factors [9]. Proteasome-assembling chaperones 1-4 form two main chaperone 
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complexes, PAC1•PAC2 and PAC3•PAC4, which guide the formation of the a-
ring [9]. b-ring assembly is in turn mediated by another chaperone, proteasome 
maturation protein (POMP) [9,179]. POMP additionally localizes the forming 
proteasome complex to the endoplasmic reticulum (ER), where majority of 
mammalian proteasomes are constructed [9,179]. The b7 subunit is added as a 
last step, creating a half proteasome (15S) [9]. The incorporation of b7 prompts 
the dimerization of two 15S complexes, and at the same time, the b-subunits 
undergo autocatalytic cleavage, becoming activated [180,181]. However, not all 
proteasomes are built equal: in the yeast S. cerevisiae a second copy of a4 subunit 
can replace a3, with no apparent adverse effects for the organism [182,183]. a4-
a4 proteasomes have also been detected in mammalian cells, which could 
indicate that this alternative assembly process is evolutionarily conserved, though 
it has not yet any known function [184]. 
 
The two 19S sub-complexes, the lid and the base, are constructed separately [9]. 
Base-specific chaperones herd the six AAA+ ATPases Rpt1-6 into forming a ring 
by binding with distinct subunits, inhibiting at the same time 19S DUB and 
ATPase activity [30,181]. The construction of the lid sub-complex is thought to 
proceed in several steps [9], completed by the addition of Rpn12 [30,185]. This 
triggers a conformational change, enabling the lid and the base to merge together 
through their mutual association with Rpn10 [30,185]. Proteasome assembly may 
also be organized differently, depending on prevailing conditions: for example in 
yeast a stress-induced proteasome assembly chaperone ATPase dedicated 
chaperone of 17 kDa (Adc17) facilitates 19S assembly following the increased 
need for more proteasomes [186]. 
 
In contrast, the process of proteasome disassembly is poorly understood. The 
proteasome is known to be for the most part a relatively stable complex, but it is 
sometimes disassembled, or even fully degraded in response to inhibition and 
different types of stress. 19S subunits Rpt5, Rpn2 and Rpn10 can be cleaved by 
Caspase-3, thereby dissociating the lid from the base and obstructing ubiquitin-
mediated degradation [187]. Yeast has a specific pathway for the removal of non-
functional proteasome subunits, which are then degraded by the proteasome 
[188]. Further, entire proteasome complexes can be directed to degradation in the 
lysosome [189,190]. Oxidative stress also induces the dissociation of 26S into its 
respective sub-complexes; a process that is in part mediated by Heatshock protein 
70 (Hsp70) [191]. 
32 
 
1.5.3. Post-translational modifications 
 
Multiple post-translational modifications (PTMs) are present on the proteasome 
at any given time. Proteomic analysis in yeast has identified more than 345 
different PTMs, belonging to 11 types [192]. The same site may also host more 
than one type of modification [193]. Subunits are altered through various post-
translational modification mechanisms, such as phosphorylation, acetylation, 
myristoylation, ubiquitination, O-linked N-acetyl-glucosamine (O-GlcNAc) 
modification, S-glutathination and oxidation [194,195]. Table 2 lists 
proteasomal PTMs with a known target and an identified effect on the 
proteasome. Several hundred phosphorylation sites alone have been detected, 
present on every proteasome subunit [196]. As a consequence, the proteasome is 
reversibly phosphorylated in variety of ways, as environmental cues both from 
within and without the cell result in fine-tuning of its function [196]. 20S and the 
19S base seem to be more prone to phosphorylation than the lid subcomplex 
[196]. Subunit phosphorylation is also necessary for their incorporation into the 
proteasome [197]. Interestingly, though many kinases have been identified in 
proteasome phosphorylation, only one proteasome-associated phosphatase has 
thus far been characterized: nuclear protein ubiquitin-like containing CTD 
phosphatase 1 (UBLCP1), which negatively regulates proteasome function in the 
nucleus, promoting disassociation of the 26S into free 20S and 19S complexes 
[198]. 
 
Ubiquitination of proteasome subunits is also an important post-translational 
modification. In yeast, Rpn10 monoubiquitination reduces substrate binding 
[199]. A similar effect was observed in mammalian proteasomes following 
proteasome inhibition, where ubiquitination of ADRM1(Rpn13) decreased 
substrate binding, and caused a 80%-90% drop in the processing of model 
ubiquitinated substrates [200]. Post-translational modifications on the 
proteasome are highly dynamic, depending on e.g. cellular localization of the 
complex, and modulators present in its immediate area. The various PTM 
methods increase proteasome plasticity, and the ability of the UPS to respond to 






Table 2. Post-translational modifications on the proteasome with a known target 
and effect. 
Target Modification Effect 
 20S  phosphorylation  ­¯ proteasome activity 
 20S  poly-ADP ribosylation 
 ­ nuclear proteasome activity and  
 histone degradation 
   a4  phosphorylation  ¯ proteasome activity 
   a5  S-gluthatiolation  20S gate opening, proteasome activity 
   a6, b3, b6, b7  acetylation  ­ proteasome activity 
   a7  phosphorylation  ¯ substrate affinity, 26S stability 
 19S  phosphorylation  ­ ATPase activity 
   Rpn2  phosphorylation  ¯ proteasome activity 
   Rpn6  phosphorylation  ­ proteasome activity 
   Rpn10  ubiquitination  ¯ substrate binding 
   Rpn13  ubiquitination  ¯ substrate binding 
   Rpt2  N-myristoylation  nuclear proteasome localization 
   Rpt2  O-GlcNAc  ¯ proteasome activity 
   Rpt6  phosphorylation 
 ­ proteasome activity, ¯ proteasome  
 assembly 














1.5.4. Proteasome-interacting proteins 
 
Multiple proteasome-interacting proteins (PIPs) have been identified, but their 
roles on the proteasome remain for the most part unclear, or even contradictory. 
For example, PI31 has been described to inhibit the proteasome in vitro [201], 
but not in vivo [202]. Other studies concluded that PI31 preferentially associates 
with the canonical 20S [81], and induces dissociation of 20S from its activators 
[201,203]. Conversely, it may also only be a regulator of the immunoproteasome 
[202]. Another study reported that in the fruit fly Drosophila melanogaster, PI31 
is a positive regulator of 26S and a negative regulator of free 20S [204]. Yet 
another study described PI31 having no effect on either proteasome content or 
function, and that any observed influence could be proteasome type or cellular 
context specific [205]. Taken together, the affiliation of PI31 with the proteasome 
is ambiguous. Another protein, extracellular mutant protein-29 (Ecm29) is also 
known to associate with the proteasome [206]. In yeast, it directly inhibits 
proteasome activity [207,208], and regulates proteasome assembly [209]. Ecm29 
also induces dissociation of the 
proteasome into 19S and 20S sub-
complexes in response to oxidative 
stress [210-212]. In addition, shuttling 
factors (e.g. Rad23, Ddi1and Dsk2; see 
Figure 3) also associate with the 
proteasome. They bind to Rpn1, Rpn10 
and Rpn13 subunits of the 19S through 
their UBL-domains, and to 
ubiquitinated substrates through their 
UBD-domains, delivering them to the 
proteasome for degradation [45]. Thus, 
several proteins associate with the 
proteasome, sometimes transiently, 
possessing regulatory functions that can 
affect e.g. proteasome activity or 
assembly. Further studies are needed to 
identify other prospective proteasome 
binding partners, and to discern their 
varying roles on the complex. 
 
Figure 3. Shuttling factors and DUBs 
associating with the proteasome. 
Proteasome subunits Rpn1, Rpn10 and 
Rpn13 serve as anchor points. Image 
modified from Darcy et al., 2015. [26]   
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1.5.5. Proteasome-associated deubiquitinating enzymes 
 
A special subclass of deubiquitinases is formed by the proteasome-associated 
DUBs in charge of substrate deubiquitination, prior to its unfolding and 
degradation by the proteasome. Ubiquitin bound to the substrate can impede 
substrate entry, and substrate-free Ub-chains can potentially become stuck on the 
proteasome. Proteasome-associated DUBs perform several essential functions, 
both facilitating and inhibiting substrate degradation, all the while maintaining 
proteasome functionality [134,135]. Most eukaryotic organisms have three major 
proteasome-associated DUBs: POH1/Rpn11 [134,135], USP14/Ubp6 [46] and 
UCHL5/Uch37 [47]. Rpn11 is a metalloprotease, while USP14 and UCHL5 are 
both cysteine proteases [122]. The endopeptidase activity of Rpn11 requires 
ATP-hydrolysis and intact proteasomes [134,135], while UCHL5 (and 
potentially USP14) is an ATP-independent exopeptidase [122]. S. cerevisiae 
proteasomes lack UCHL5, and only a small constituent of both mammalian and 
yeast proteasomes contain USP14/Ubp6 [213-215]. While Rpn11 is a 
stoichiometric subunit of the proteasome, UCHL5 and USP14 both reversibly 
associate with the 19S base (see Figure 3). Their DUB-activity is increased, or 
in the case of UCHL5 activated, with proteasome association [26]. USP14 
reversibly associates with Rpn1, which increases its DUB-activity 1000-fold, 
probably through conformational changes that make the catalytic site of USP14 
accessible [46,216]. Other DUBs have also been described to occasionally 
associate with the proteasome, including Usp5, Usp7, Usp9x, Usp13, Usp15 and 
Usp38, but their possible role in context with the proteasome is not well 
understood [200,217]. 
 
Substrate affinity of the proteasome-associated DUBs depends on position, 
length, and number of the Ub-chains present on the substrate [28]. These three 
DUBs are proposed to function collaboratively, and in specific order [28]. 
UCHL5 and USP14 most likely act before commitment to proteolysis, and Rpn11 
during substrate translocation [28]; in a simplified view, Rpn11 promotes 
degradation [218,219], while USP14 and UCHL5 antagonize it [117,218-220]. 
Under normal circumstances, cells possess a large pool of free ubiquitin (~20 
µM) [221]. It is maintained by the proteasome-associated DUBs; deletion of 
USP14/Ubp6 alone leads to difficulties in ubiquitin recycling, limiting 
proteolysis and growth potential [222,223]. Rpn11 is crucial for cell survival in 
yeast and metazoan systems [224,225], and essential for 19S structure and 
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activity [225,226]. Rpn11 cleaves an Ub-chain off close to its base, releasing the 
whole chain at once [28]. Inactivation of Rpn11 traps substrates on the 
proteasome [227]. In yeast, Ubp6 is not necessary for survival, although it has an 
important role in the context of metabolic stress [228]. Mammalian proteasomes 
suffer no structural modifications, and there is no difference in the accumulation 
of polyubiquitinated substrates after knockdown of USP14 [220]. Interestingly, 
majority of USP14 proteins appear not to be associated with the proteasome, 
suggesting that it has roles beyond 26S [220]. Dual inhibition of USP14 and 
UCHL5 impedes cell growth and degradation, causing accumulation of 
polyubiquitinated substrates in human cancer cell lines [226]. Conversely, RNAi 




This thesis focuses on UCHL5/Uch37, and its C. elegans orthologue, ubiquitin 
C-terminal hydrolase 4 (UBH-4). The apparent monomeric molecular size of 
UCHL5 is 37 kDa [229], and it is 329 amino acids long [230]. UCHL5 structure 
and function are well conserved throughout evolution [230]. Human UCHL5 
presents as multiple different splice variants [231]; however, virtually nothing is 
known about their potential different functions or expression profiles. Though S. 
cerevisiae has no known orthologue of UCHL5 [10], S. pombe has a seemingly 
redundant orthologue, ubiquitin C-terminal hydrolase (Uch2) [232]. UCHL5 
association with the proteasome is reversible [52,230,233,234], and it also 
associates with the INO80 chromatin remodeling complex, although its role there 
remains obscure [59,235-238]. 
 
A central six-stranded b-sheet flanked from each side by a-helixes composes the 
catalytic domain of UCHL5 [133]. The C-terminal KEKE-motif (a domain 
enriched in alternating lysine (K) and glutamic acid (E) residues) extension of 
UCHL5 binds to both Rpn13 and NFRKB/INO80G-subunit through their 
DEUBiquitinase ADaptor (DEUBAD) domains [52,230,233,235]. UCHL5 is 
also linked to Rpn2 via Rpn13 [219]. When not bound by INO80 or the 
proteasome, UCHL5 is DUB inactive, and exists as a mixture of different 
oligomeric states in the cytosol, where two UCHL5 active sites sterically obstruct 
substrate access [229]. Binding to Rpn13 induces conformational changes that 
activate UCHL5 DUB activity [52,230,233]. In contrast, association with 
NFRKB is highly DUB inhibitory [229]. Transient incubation with Rpn13 or 
37 
 
UCHL5-lacking 26S restored UCHL5 DUB activity, without disassociating 
UCHL5 from the INO80 complex [235,239,240]. This activation was abrogated, 
however, when Rpn13 was removed. UCHL5 can trim entire polyubiquitin 
chains at once, but in the context of the proteasome it removes ubiquitin one 
molecule at a time from the distal end of the chain [219], cleaving both Lys48- 
and Lys63-linked chains [117]. UCHL5 is thought to save poorly or ineptly 
ubiquitinated substrates from degradation [219,220,241]. UCHL5 also exhibits 
substrate specificity, e.g. by promoting the degradation of nitric oxide synthase 
and Ikb-a [242]. This suggests that UCHL5 has a dual role in protein turnover, 
promoting the degradation of some substrates, and inhibiting the degradation of 
others [26]. 
 
UCHL5 has been implicated in Alzheimer’s disease [243], and its deletion causes 
embryonic lethality in mice [244]. Both Rpn13 and UCHL5 are essential for cell 
cycle progression, as deletion of either gene caused G0/G1 stalling in vitro [238]. 
High levels of UCHL5 have been reported in pulmonary fibrosis, where UCHL5 
deubiquitinates the transcription factors Mothers against decapentaplegic 
homolog 2 (SMAD2) and SMAD3, promoting transforming growth factor-b 
(TGF-b) stabilization and the expression of profibrotic proteins (e.g. fibronectin) 
[245,246]. Concurrently, UCHL5 functions as an agonist of the SMAD specific 
E3 Ubiquitin protein ligase 2 (SMURF2), following UCHL5 recruitment by 
SMAD7 into the TGF-b inhibitory SMAD7-SMURF2 complex, in this manner 
stabilizing TGF-b from two fronts [136,247-251]. Several distinct roles for the 
UCHL5 on the proteasome have been suggested, from trimming poorly 
ubiquitinated proteasome substrates [219], relieving ubiquitination status of 
proteasome subunits [252] to blocking substrate access to the proteasome [252]. 
It is possible that the role of UCHL5 on the proteasome is a dynamic mixture of 
these and other functions not yet identified. 
 
 
1.6. The ubiquitin-proteasome system in the regulation of proteostasis in aging 
 
The inevitable aging process affects effectively all cellular pathways and 
processes in most organisms, except for biologically immortal creatures such as 
Hydra [253]. Aged cells must content with an increased amount in misfolded or 
surplus proteins, resulting in elevated levels of proteotoxic stress [254]. This is 
often thought to be accompanied with a collapse in proteostasis, in part caused 
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by a decrease in proteasome activity [255]. Several signaling pathways regulate 
aging, often with a regulatory role in maintenance of proteostasis [256,257]. The 
best characterized of these pathways is Insulin/IGF-1 signaling (IIS). Reduced 
IIS has been shown to delay the onset of many age-related diseases [254], extend 
lifespan in C. elegans, and correlate with longevity in humans [258,259]. In C. 
elegans, an important IIS effector is the sole nematode FOXO homolog DAF-16, 
which regulates the expression of multiple downstream genes [258]. Reduced IIS 
phenotype protects from proteotoxicity [260,261] in part by delaying the onset of 
age-dependent protein aggregation, which is mediated most likely through the 
modulation of the proteostasis network [262]. Different mechanisms exist to 
counter the accumulation of misfolded proteins, known collectively as the 
unfolded protein response (UPR) [8]. These pathways are coupled to the protein 
degradation machinery of the cell, including the UPS [8,263]. 
 
For some time, the consensus has been that protein quality control systems, 
including UPS activity, decline with age [264]. Notably, UPS dysfunction is 
present in several age-related neurodegenerative disorders, e.g. Alzheimer’s 
[265], Parkinson’s [266], or Huntington’s disease [267]. Further, a decline in the 
expression of proteasome subunits has been observed in aging mice [268,269]. 
Aging-associated decrease in proteasome function has also been perceived in 
many rat and human tissues [270-274]. Supporting this observation, the 
promotion of proteasome activity increased lifespan in several model organisms 
[275-277]. However, the expression of several proteasome subunits was 
upregulated in aging C. elegans [278]. Additionally, following proteotoxic stress, 
the upregulation of Rpn6 alone was enough to promote proteasome activity, and 
extend lifespan in C. elegans [279]. The observed age-dependent decline in UPS 
output in multiple systems could be the result of various factors, such as changes 
in proteasome composition and structure, or availability of other UPS members 
[194]. Further, changes in proteasome post-translational modifications [280,281] 
or amassing oxidative damage can also be at fault [282]. 
 
However, it is also possible that the two pathways of proteasome mediated 
protein degradation are affected differently in response to aging. Though in some 
cases there appears to be a tissue-specific increase in 26S activity [283,284], the 
ability of 20S to degrade oxidized proteins declines, resulting in the accumulation 
of harmful oxidized proteins [273,285]. This could cause accumulation of 
undegradable aggregates, which then stall and trap the proteasomes binding with 
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them to attempt their degradation [286-288]. Taken together, the details of UPS 
function and proteasome activity in different cells and tissues of aging organisms 
remain a fascinating and important question for future research. 
 
 
1.7. The ubiquitin-proteasome system in cancer 
 
The UPS has been implicated multiple times in malignant neoplastic formation, 
due in part to its regulation of many cell cycle proteins (e.g. CDK inhibitors and 
cyclins), and apoptotic factors (e.g. p53 and caspases) [289-294]. Perturbations 
of the UPS cause aberrant stabilization, or loss of important regulatory proteins, 
disrupting the normal balance of these molecules, thus contributing to 
tumorigenesis [295,296]. UPS is often found to be hyper-activated in tumor cells 
[293,294,297-299], though the increase in activity might not be sufficient to 
alleviate the increase in accumulating proteasomal substrates [299]. In contrast, 
CSCs (cancer stem cells) have been reported to exhibit relatively low proteasome 
activity in some studies [300,301]. This may confer protection from host immune 
attack, following decreased antigen presentation by these cells [60]. However, 
though proteasome activity in CSCs may be low, expression of some proteasome 
subunits is upregulated [60]. 
 
Several components of the UPS, in addition to proteasome activity itself, can be 
affected in cancer. Deregulation of multiple E3s is associated with the 
development, progression and therapeutic response of several cancer types [98]. 
Many DUBs are also prominently connected to cancer in a similar manner, 
including (but not limited to) USP4, USP6, USP8, USP14 and USP28 [302]. In 
hepatocellular carcinoma, high UCHL5 expression is linked to cancer recurrence 
[303]. In the same cancer type, UCHL5 was also found to associate with glucose-
regulated protein 78 (GRP78) [304], a Hsp70-family chaperone, which is 
overexpressed in various cancers [305-308]. In esophageal squamous cell 
carcinoma and epithelial ovarian cancer, high UCHL5 expression correlated with 
poor prognosis and cancer recurrence [309,310]. Further, high levels of UCHL5 
expression have been described in breast, vulva and parathyroid cancers, and 
increased UCHL5 activity was reported in cervical cancer [311]. Both USP14 
and UCHL5 are expressed in high levels in multiple myeloma, and their 




1.7.1. Targeting the ubiquitin-proteasome system in cancer therapies 
 
Malignant neoplastic cells exhibit amplified sensitivity for proteasomal 
inhibition [313], due most likely to the increased proliferation and protein 
turnover in these cells, requiring increased proteasomal degradation [314]. 
Proteasome inhibitors targeting the catalytic activity of the 20S CP have been 
used in treatment of cancer since 2003, e.g. in multiple myeloma and mantle cell 
lymphoma [315], and they are currently being investigated for use in solid 
tumors, though thus far without promising results [316]. As a treatment form, 
proteasome inhibition is effective, resulting in higher disease free- and overall 
survival for many patients [317]. However, the use of proteasome inhibitors can 
also cause many difficult off-target effects, such as severe gastrointestinal (GI) 
side-effects [317] and peripheral autonomic neuropathy [318]. These inhibitor-
linked toxicities can be dose-limiting, ranging from minor to severe [319]. 
Additionally, treatment resistance is a common problem, especially upon cancer 
recurrence [320,321]. Refining of combinatory treatments which include 
proteasome inhibitors might broaden the usefulness of these drugs, also in other 
cancer types [322].  
 
In view of the multiple problems associated with the use of current proteasome 
inhibitors, new members of the UPS are being explored for targeted treatment. 
Tumor cells are subject to constantly changing conditions, and their dynamic 
plasticity convey a large magnitude of survival potential [98]. This involves e.g. 
the recruitment of many downstream effectors, which is why spatial and temporal 
deregulation of E3s is considered a viable therapeutic option in many cancers, 
through the selective inhibition of specific E3s [323]. The aim would be to affect 
only the target proteins of the E3 involved, with presumably fewer off-target 
effects [323]. Clinical trials are in progress for evaluating various small 
molecules that target E1 and E3 enzymes [324-327], and drugs binding and 
inhibiting E3s are already approved for use [328]. 
 
One of the more promising groups of relatively new treatment targets are DUBs, 
especially the proteasome-associated DUBs Rpn11, USP14 and UCHL5. 
Deubiquitinases are associated in various cellular processes, which are often 
found altered in cancer, including cell cycle control and apoptosis [26]. DUBs 
are able to modulate substrates in a selective and specific manner [329], and their 
targeting could provide the opportunity to influence only certain aspects of 
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pathological signaling pathways, instead of globally affecting Ub-mediated 
protein degradation [330]. DUB inhibitors in development range from pan-
enzyme inhibitors to specific inhibitors, targeting just one DUB [330]. Expected 
effects include e.g. accumulation of polyubiquitinated substrates, disruptions in 
Ub-recycling, and slower polyubiquitin disassembly [331], all of which would be 
deleterious for cancerous cells, and potentially induce their apoptosis. As some 
DUBs are substrate specific, targeting just one or few could limit the more serious 
off-target effects, in a similar manner as when targeting specific E3s, providing 
increased therapeutic efficacy [332]. In addition, DUBs are presumed to be easier 
to target than E3s, because E3 enzymes lack universal catalytic residues, unlike 
DUBs, which are for the majority cysteine proteases [26]. Inhibitors for 
proteasome-associated DUBs are already in development: for example, inhibition 
of USP14 with IU1 reduced chain trimming, and increased proteasomal 
degradation, which could be beneficial additionally in protein aggregate diseases, 
such as Alzheimer’s disease [218]. Another inhibitor, b-AP15, provides dual 
inhibition of both USP14 and UCHL5, and displays extensive anti-neoplastic 
activity against solid tumors [333]. b-AP15 has also exhibited promising results 
in multiple myeloma in animal models [312]. In addition, WP1130-mediated 
inhibition was shown to target several DUBs, including USP14 and UCHL5, 
causing accumulation of polyubiquitinated substrates [331]. 
 
Lastly, targeting 19S subunits might favor 20S association with alternate 
activators, such as 11S, which in turn would promote production of anti-
tumorigenic peptides for the MHC I complex [60]. In combination with new 
immune response promoting therapies this might provide beneficial results [334]. 
UCHL5 binding partner Rpn13 has also emerged as a therapeutic target in 
different cancers, including Bortezomib (a canonical proteasome inhibitor) 
resistant multiple myeloma [335]. Further, the immunoproteasome is upregulated 
in inflamed tissues and cells of the immune system, replacing conventional 
proteasomes to a high degree [82-84]. Immunoproteasome inhibition in mice 
exhibited a broader therapeutic window and less side-effects than general 
proteasome inhibition, and inhibition of the LMP7/b5i subunit shows great 
promise in colorectal cancer [336]. Considering the variation in the expression of 
tissue-specific proteasomes and their subunits, using proteasome inhibitors with 
such narrow range could potentially be used to target distinct diseases, such as 
autoimmune diseases, with fewer off target-effects. 
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2. Gastrointestinal cancers 
 
Cancer is a heterogeneous disease, and by its simplest definition, a sickness of 
the cell cycle; cancer patients suffer unchecked cellular growth and proliferation, 
with ultimately fatal results. Cancer is often considered a disease of the old, as 
more than half of cancer patients are over 70 [337]. Aging and cancer are in part 
caused by similar processes: the time-dependent accumulation of cellular damage 
[255]. Gastrointestinal cancers constitute a varied group of malignant neoplasms, 
with an origin in different tissues and organs of the digestive system. They 
present varying modes of development and degrees of aggressiveness, and they 
also share some common predisposing environmental factors and genetic traits. 
Three major gastrointestinal cancers are examined in this thesis: colorectal cancer 
(CRC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). 
 
During carcinogenesis, cellular signaling pathways are repurposed into tumor 
development following the silencing and/or activation of one or more key 
molecule(s); either via mutation, or by through some other processes, e.g. 
epigenetic changes [338]. This results in the constitutive activation or 
suppression of often multiple pathways, all contributing towards harmful 
neoplastic transformation [339]. Common signaling pathways found altered in 
CRC, GC and PDAC include, but are not limited to, Wnt-signaling, the mitogen-
activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK) 
pathway, the phosphatidylinositol-3-kinase/protein-kinase B/mechanistic target 
of Rapamycin  (PI(3)K/AKT/mTOR) pathway and tumor protein 53 (TP53) 
[340], which are all classic oncogenic signaling pathways. 
 
A list of shared genes affected (e.g. through mutation, epigenetic modification, 
amplification) in CRC, GC and PDAC is collected in Table 3. Loss of TP53 is 
common in all GI cancers [341]. Increased b-catenin expression is also frequent, 
often caused by inactivation of the adenomatous polyposis coli (APC) gene 
[340]. However, within a given tumor there are generally several clones or 
families of tumor cells, which have developed in response to the significant 
selective pressure caused by the abnormal conditions within the tumor itself, and 
the surrounding stroma [342]. As a result, prognosis, responsiveness to treatment, 
and emergence of resistance can be erratic and difficult to predict, due to the 
dissimilar nature in biological and genetic modifications found within the same 
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tumor [343, 344]. Many cancer cells also exhibit a dynamic range of molecular 
and phenotypic states during tumor growth and development [345]. 
 
 
Table 3. Common altered genes in CRC, GC and PDAC. 
Gene CRC GC PDAC 
ALK X X X 
AMER1 X X  
APC X X  
ARID1A X X X 
ATM X X  
BRAF X X  
b-CATENIN X X  
CDKN2A X X X 
DCC X X  
E-CADHERIN X X  
EGFR X X  
HER2 X X  
KRAS X X X 
mTOR X X  
NOTCH X X  
p16 X X X 
PI3K X X  
PTEN X X  
SMAD4 X X X 
TGF-b X X  
TP53 X X X 
VEGFR X X  
X:  >5% of cases affected. Alteration frequency checked 
according to The Cancer Genome Atlas (TCGA) 
https://portal.gdc.cancer.gov. [339, 346-357] 
 
 
Metastases spreading out from primary tumors develop similarly in a stepwise 
process, much like the initial tumorigenesis. Abnormal epithelial cells 
dedifferentiate through epithelial-to-mesenchymal transition (EMT) to achieve 




circulating tumor cells (CTCs) [358]. In the blood, CTCs can assume 
mesenchymal or epithelial phenotype, or distinct characteristics of both [359]. 
However, mesenchymal CTCs almost certainly harbor a higher capacity for 
metastasis, due to their better ability to extravasate back into tissues [360]. These 
secondary tumor sites often have a very different mutational load compared to 
the primary tumor, which again might have a significant effect on treatment 
responsiveness and prognosis, especially upon cancer recurrence [343]. This 
should be taken into account in the use of biomarkers, which are usually only 
sampled at the primary tumor site [349]. While some studies report a high degree 
of concordance between primary tumors and metastases (at least in CRC), there 
exists a possibility of complex heterogeneity, in part caused by the differences 
found in tumor microenvironments (TME) present at distant metastatic sites 
[361,362]. 
 
Accurate cancer classification is required for correct diagnosis and treatment of 
the patient. Therapy options in GI cancers depend largely on the stage of the 
disease upon diagnosis, and the need for pre- or postoperative adjuvant therapy 
should also be assessed on an individual basis [363]. The anatomic site and 
histologic appearance of the tumor are critical for determining these factors; 
however, morphologically similar cancers can vary wildly in their course and 
response to treatment [364]. The globally used TNM Classification of Malignant 
Tumors (TNM staging; see APPENDIXES) considers the type of the original 
tumor (size, involvement with nearby tissues; T), lymph node-involvement (N) 
and metastatic status (M). The 8th iteration of the system is recommended for use 
since the beginning of 2018. 
 
 
2.1. Colorectal cancer 
 
The large bowel is divided into cecum, colon and rectum, which comprises the 
final straight part of the gut. Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in the world, and also third in cancer-related death [365]; of all 
GI cancers, CRC is the most common [366]. Nearly 20-30% of CRC cases are 
diagnosed at an advanced stage, and 40-50% of those discovered in the early 
stages suffer a relapse [348]. 5-year survival rate varies from 75%-90% for stage 
I disease, to less than 10% in metastatic CRC [348, 367]. Colorectal tumors 
originate more often on the left side of the gut [366], and different genetic 
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aberrations are also associated with each side [346]. Based on anatomy and 
embryonic origin, CRC is divided into distal colon cancer and rectal cancer, both 
arising from the hindgut, and proximal colon cancer, arising from the midgut 
[346]. 
 
Due to the elevated turnover rate of the intestinal epithelium, it is a major site for 
colorectal carcinogenesis [368-370]. Tumors often progress slowly, usually 
forming over a period of 10-15 years [366]. Their development starts with 
abnormal transformation of gastric epithelium; aberrant crypt foci (AFC) form in 
the mucosal crypts located in the rectal or colonic inner lining, creating the first 
precursors to cancer [371]. AFCs progress into adenomatous polyps or adenomas 
[372,373], although it is postulated that they may themselves directly become 
cancerous [374,375]. Over 95% of all CRC cases are adenocarcinomas [373], 
which develop from the mucosal glands lining the gut [373]. Other CRC types 
include intestinal lymphomas and sarcomas, carcinoid tumors (originating from 
intestinal hormonal cells) and gastrointestinal stromal tumors (originating from 
the interstitial cells of Cajal or ICCs) [373].  
 
Akin to all cancers, CRC is a consequence of different factors, including inherited 
elements and traits acquired during individual lifetime. Genetic factors influence 
approximately 35% of CRC, both protecting from, or causing cancer 
development [376]. While most cases of CRC are considered sporadic [377], 
approximately 5%-6% of CRC patients have an identified inherited 
predisposition [367,378]. Hereditary colorectal syndromes include e.g. familial 
adenomatous polyposis (FAP; variants include attenuated FAP and familial 
colorectal polyposis/Gardner’s syndrome), juvenile polyposis syndrome (JPS), 
hereditary nonpolyposis colorectal cancer (HNPCC or Lynch disease), hereditary 
mixed polyposis, MYH-associated polyposis (MAP), Peutz-Jeghers syndrome 
(PJS) and serrated polyposis syndrome (SPS) [346,350]. Of these, HNPCC is by 
far the most frequent, consisting of approximately 2-5% of all CRC cases [346]. 
Sporadic CRC is thought to progress with successive accumulation of somatic 
mutations in both tumor suppressor and proto-oncogenes, leading to malignant 
transformation, where the total accumulation of genetic modifications is 
important, rather than their specific order [374]. One study identified an average 
of 80-90 mutated genes per colorectal tumor [379,380], of which 15 were 




The three main pathways related to oncogenic development of both hereditary 
and sporadic CRC are the chromosomal instability (CIN) pathway, the mismatch 
repair pathway (MMR) and the CpG island methylator phenotype (CIMP), which 
all have distinct phenotypes, and are linked to specific genetic and molecular 
signatures [347]. All three can be present separately or in combination in a given 
tumor, greatly affecting e.g. tumor malignancy and other clinical traits, such as 
treatment response [367,381]. The CIN pathway is best known in association 
with the well-known adenoma to carcinoma sequence [347,382] and is present in 
70% of all CRC [383]. It describes the classical stepwise transformation of 
regular colonic mucosa to carcinoma, with multiple accumulating mutation 
events on the way [347]. The MMR pathway is sometimes also called 
microsatellite instability (MIN/MIS/MSI), which is a phenomenon associated 
with this pathway. Microsatellites are 1-4 nucleotide long sequences of repetitive 
noncoding DNA, which are found throughout the genome [347]. DNA mismatch 
repair (MMR) proteins are a family of genes that repair mutations occurring 
during the replicative cycle, protecting microsatellite stability [347]. Both genetic 
and epigenetic silencing of these genes leads to accumulating mutations, causing 
MSI and hastening oncogenic transformation [384]. CpG islands are CG-rich 
sections of DNA present in approximately half of all genetic promoters [382]. 
The CIMP pathway is characterized by the presence of ubiquitous CpG island 
methylation, causing aberrant gene silencing [385]. 
 
Genes altered in CRC are listed in Table 3. The best characterized genetic defect 
associated with CRC are APC mutations, the loss of which seems to be an early 
event in CRC tumorigenesis [386]. Approximately 80% of all sporadic CRC 
tumors have these mutations [387]. APC is a member of the Wnt pathway, which 
regulates the cytoplasmic levels of b-catenin [387]. Increased b-catenin levels 
induce expression of a proliferation regulator, MYC [388]. Together, APC, b-
catenin and MYC are involved in maintaining cell integrity, and loss of APC 
often leads to decreased cell-to-cell adhesion, and an increase in cell migration 
and metastatic potential [388]. The mutation of V-ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS) is common both in the primary tumor and 
metastatic tumor sites [389]. RAS mutations (BRAF/KRAS/NRAS) are often 
accompanied by phosphorylation of ERKs, and the activation of the ERK/MAPK 
pathway [390]. RAS signaling is mediated also through PI(3)K [391], resulting 
in promotion of cell survival and growth [348]. In contrast, the PI(3)K inhibitor 
phosphatase and tension homolog (PTEN) is inactivated in 10% of CRC cases 
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[348]. The regulatory oncogenes MYC and CDK8 are rarely mutated in CRC, 
but their amplification is present in approximately 10%-25% of tumors 
[392,393], and alterations in MYC activity are present in approximately 95% of 
CRC [348]. The most crucial altered CRC genetic pathways are Wnt, MAPK, 
PI(3)K, TGF-b and TP53 [348]. Of these, most often affected is the Wnt pathway: 
constitutive activation is found in approximately 90% of studied tumors [348, 
394]. Only 5% of adenomas harbor p53 mutations, but they are more common in 
malignant polyps (50%) and metastatic CRC (75%) [395]. 
 
Though the genetic background of the patient plays a significant role, many 
environmental traits predispose patients to CRC. Known risk factors include 
obesity, lack of exercise, use of alcohol and tobacco, as well as e.g. fat-rich, high-
meat and fiber-deficient diet [373,396-399]. In addition, high levels of insulin 
and chronic intestinal inflammation (e.g. Crohn’s disease, ulcerative colitis) have 
been linked with higher risk of CRC [373,400]. Globally, patients over 50 years 
old are more likely to develop CRC [401], and men are two times more likely to 
fall ill than women [369]. In contrast, diet rich in fiber [402] or fish (particularly 
consumption of fish oil) [403], high intake of vitamin D or calcium [404], and 
regular aspirin use at least twice per week [405] all reduce risk of CRC. 
Interactions between environmental and genetic factors converge to affect 
individual probability to develop CRC. 
 
The Dukes’ system for CRC staging was developed in 1932 by the British 
pathologist Cuthbert Dukes [406]. Originally used only for colonic tumors, 
Dukes’ has been later modified, thereby creating the Astler-Coller modification 
(MAC), Tunrbull modification (1967) and the Australian Clinico-Pathological 
Staging (ACPS) modification [407-409]. However, the Dukes’ system has been 
widely replaced by the TNM staging system in clinical praxis (described in 
APPENDIX 1A and 1B). Dukes A corresponds to stage I, Dukes B to stage II, 
Dukes C to stage III and Dukes D to stage IV of the current TNM system 
(APPENDIX 1A). Characterization of CRC based on molecular subtypes rather 
than histology has been attempted by different groups [392,393,410-413], 
classifying 3-6 different molecular CRC subtypes depending on the study. At 
least in the case of Sadanandam et al., the characterized subtypes seemed to have 
both prognostic and therapeutic value [411]. The Colorectal Cancer Subtyping 
Consortium (CRCSC) has also attempted molecular classification [414]. Their 
categories include four different molecular CRC subtypes (CMS1-4), and a fifth 
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less clearly defined subgroup, all displaying similarities in molecular, clinical and 
pathological traits [414]. Despite these advancements, some CRC tumors still 
defy classification, and molecular CRC classification methods require 
improvement before they can be applied in a clinical setting. More precise 
molecular subgrouping could clarify therapy options, and provide more accurate 
prognostic information [346, 348]. 
 
CRC is unfortunately often symptomless until tumors have reached a large size 
[366]. Common symptoms connected to CRC include rectal bleeding, changes in 
bowel movements and abdominal pain, but they are also associated with other 
gastrointestinal conditions, and their usefulness in diagnosing CRC is estimated 
to be less than 10% [415]. Treatment options involve surgery, chemotherapy, 
combined radio-chemotherapy and more recently, monoclonal antibody-based 
therapies directed at the vascular endothelial growth factors (VEGFs) or 
epithelial growth factor receptor (EGFR) [336]. While adjuvant treatment offers 
no survival benefit for stage I patients, a well-chosen treatment may improve both 
life quality and length of stage III patients and stage II patients presenting adverse 
prognostic factors (such as blood vessel- or perineural invasion) [350]. In recent 
decades, improvements have also been made in the treatment of patients with 




2.2. Gastric cancer 
 
The stomach is divided into fundus, corpus (body) and pyloric antrum. Gastric 
cancers (gastric carcinomas, GCs) are globally the fifth most common cancer 
with third highest cancer-related mortality [354,416,417]. With a 5-year survival 
rate of less than 30% [418-420], GC is also often highly invasive and metastatic 
[421-423]. The biology of gastric cancer is mixed, evolving from various 
epigenetic and genetic alterations. Similarly to CRC, GC develops with the 
progressive accumulation of adverse gene modifications in gastric epithelial cells 
that ultimately contribute to malignant neoplastic transformation [424,425]. 
Chronic gastric infection (gastritis) coupled with intestinal metaplasia (IM) are 
crucial in early GC pathogenesis [426]. Hereditary forms of GC are rare (only 1-
3% of cases), and they fall predominantly into three types: gastric 
adenocarcinoma and proximal polyposis of the stomach (GAPPS), familial 
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intestinal gastric cancer (FIGC) and hereditary diffuse gastric cancer (HDGC) 
[426]. 
 
Classically, gastric adenocarcinomas are divided according to their histological 
subtype using the Laurén classification into intestinal or diffuse tumors [354,427-
429]. The intestinal-type adenocarcinomas typically develop glands with varying 
degree of differentiation, while diffuse gastric cancer carcinomas lack 
cohesiveness, being composed of single cells or small groups of neoplastic cells 
scattered inside the gastrine wall [354].  Table 3 lists genetic alterations found in 
GC. The genomic instability pathways relevant in the development of CRC (CIN, 
MSI and CIMP) are equally important in GC carcinogenesis [430]. Other 
pathways that are often mutated include chromatin remodeling associated genes 
[431,432], cell motility/cytoskeleton associated genes [433], Wnt signaling [340] 
and receptor tyrosine kinases [295,431,432,434-437]. The cell-adhesion 
molecule E-cadherin is more often mutated in diffuse GC, including hereditary 
diffuse GC [351].  
 
Perhaps the most well-known environmental risk factor associated with gastric 
cancer is chronic Helicobacteria pylori-infection [363,429]. Some studies 
suggest as high a risk as 75% of developing GC linked with H. pylori [438-440]. 
Similarly, the Epstein-Barr virus (EBV) is linked to GC [441]. Increased salt 
intake, smoked or spoiled food, nitrates and secondary amines increase risk of 
gastric cancer [363,442]. Other high risk factors include smoking and heavy 
alcohol use [363]. Conversely, substantial intake of raw vegetables, fruits, 
vitamins A and C, calcium and antioxidants reduce gastric cancer risk [443]. 
 
The TNM-staging system is in common use for prognostic purposes in the clinic 
(see APPENDIX 2A and 2B). Attempts have been made to develop other 
classification systems, which would be more accurate in the prognostic setting. 
World Health Organization (WHO) has introduced a new type of classification 
with the following subgroups: tubular, papillary, mucinous and poorly 
cohesive/signet ring [444]. The cancer genome atlas (TCGA) research project 
categorized four major molecular subtypes of GC tumors: Epstein-Barr virus 
(EBV)-positive, microsatellite instability (MSI), genomic stability (GS) and 
chromosomal instability (CIN) [431]. A similar study by the Asian Cancer 
Research Group (ACRG) divided gastric cancer into four different subgroups: 
MSI, microsatellite stable (MSS)/epithelial-to-mesenchyme (EMT)-positive, 
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MSS/TP53+ and MSS/TP53- [432]. In comparison to the TCGA grouping, these 
four subgroups also presented significant survival differences, as well as distinct 
clinical properties [432]. Despite these developments, reliable treatment options 
based on these molecular subtypes are not yet available [351]. 
 
Most gastric cancer patients are diagnosed at an advanced (stage III-IV) stage of 
cancer, and they are often deemed unresectable by this point [445]. In metastatic 
GC, systemic chemotherapy is currently the only available treatment option 
[446]. Regrettably, inherent and acquired treatment resistance is a large problem, 
and most patients die within a year from first diagnosis [447,448]. Gastric cancer 
symptoms can easily masquerade as other nonthreatening gastric conditions, but 
actual symptoms include anorexia, dysphagia, vomiting, gastrointestinal blood 
loss and weight loss [449]. For these reasons, the prognosis for gastric cancer 
patients in the current treatment landscape remains poor [450]. 
 
 
2.3. Pancreatic ductal adenocarcinoma 
 
Over 90% of all pancreatic cancers are classified as pancreatic ductal 
adenocarcinoma (PDAC) [451]. Even with successful resection in early PDAC, 
lymph node-negative patients have a 5-year survival of 25%-30%, and lymph 
node-positive as low as 10% [452]. Further, advanced PDAC cases consist 4% 
of global cancer related deaths [357], with all patients exhibiting a 5-year survival 
of 8% [420], and only 1% for metastatic cases [357]. Majority of genetic or 
metabolic changes underlying the development of PDAC are sporadic [357]. 
Hereditary mutation load explains approximately 5-10% of PDAC, although the 
inherited component has not been identified in most cases [453,454]. Inherited 
PDAC occurs in three distinct forms: hereditary tumor predisposition syndromes, 
and hereditary pancreatic and familiar pancreatic cancer [453,455]. Genetic 
factors increasing incidence are family history of pancreatic cancer [456], 
familial atypical multiple melanoma and mole syndrome (FAMM), familial 
breast cancer, Lynch disease, PJS and Fanconi anemia [456-458]. Though there 
is high degree of heterogeneity within tumors, primary tumors appear to share 
largely overlapping genomic traits with metastases, even if they arise from 
distinct subclones of the original tumor [459]. PDAC has also a high metastasis 




Table 3 contains a list of gene alterations present in PDAC. Gene mutations 
include the oncogene KRAS, found in chronic pancreatitis [460] and in 
approximately 90% of PDAC cases, occurring often early in tumorigenesis [461-
463]. The tumor suppressor p16, in connection with CDK inactivation, is mutated 
in almost 95% of patients, causing uncontrolled proliferation [461,462,464]. 
SMAD4 mutations are present in almost 50% of tumors, conveying abnormal 
TGF-b signaling [461,462]. SMAD4 loss is additionally connected to significant 
metastasis [356]. 75% of pancreatic cancers are TP53 mutated [461-463]. Key 
pathways altered in PDAC malignancy include EFGR signaling [465-467], 
NOTCH signaling [468,469], Hedgehog signaling [470, 471], Wnt signaling 
[472,473] and NFkb signaling [474-476], as well as various cytokines, growth 
factors and associated signaling [477-480]. 
 
Additionally, the surrounding stroma and the tumor microenvironment are very 
important for the onset and development of PDAC, both at the site of the primary 
tumor, but also in the forming of eventual metastases [481-484]. Excessive 
desmoplastic reaction induces proliferation of fibroblasts and production of 
extracellular matrix (ECM) in PDAC [339]. Stromal cells, such as active 
fibroblasts, myofibroblasts and pancreatic stellate cells, all actively contribute to 
the changing ECM composition, along with other stromal elements, such as 
multiple growth factors (e.g. TGF-b) [485,486]. Despite changes in expression 
profiles and metabolic signatures, actual genetic changes in the stroma are rare, 
though epigenetic alterations may be present especially in fibroblasts [487-490]. 
Conversely, stromal cells are also thought to induce epigenetic chances in 
pancreatic cancer cells [491]. The stroma not only promotes malignant neoplastic 
formation, but it may also form a drug delivery barrier, hindering PDAC 
treatment [357]. 
 
Environmental risk factors include smoking and obesity [456,463,492,493], 
diabetes [494], age over 50 [495], ethnicity [456,492,495,496], male gender 
[495] and the presence of chronic or inherited pancreatitis [497]. H. Pylori 
infection may increase the risk of pancreatic cancer [456,495,498]. On average, 
PDAC patients are 71 years old [357]. With only 9% of patients diagnosed with 
localized disease, majority present with either advanced or metastatic PDAC at 
the time of diagnosis [357,499-501]. PDAC is difficult to treat for multiple 
reasons, including often late onset of the disease, associated with other medical 
co-morbidities [357,499-501]. For example, at least 50% of PDAC patients also 
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suffer from diabetes [502]. PDAC has often asymptomatic progression, but 
symptoms may include weight loss, nausea, vomiting, jaundice or abdominal 
pain [503]; symptom types are connected to the location of the tumor [504]. 
 
TNM staging for PDAC is described in APPENDIX 3A and 3B. To improve 
accuracy of PDAC staging, several groups have attempted to classify PDAC 
tumors. A recent review by Fakhri and Lim [364] described four suggested 
classification systems for PDAC, which are briefly described here. Collison et al. 
used PDAC gene expression analysis, categorizing four different subgroups of 
PDAC [505]. Whole-genome sequencing and copy-number variation analysis 
also divided PDAC into four different groups [506]. Transcriptome analysis 
discovered yet four more subgroups, of which three overlapped with those 
characterized by Collison et al. [505,507]. With somewhat different approach, 
Moffitt et al. also included the surrounding stroma in their analysis, identifying 
two tumor- and two stroma-specific PDAC subtypes [506]. However, a 
comprehensive molecular and genetic staging classification system with 
prognostic or therapeutic relevance for PDAC still remains to be developed. 
 
As with many other cancer types, surgery is the only potentially curative therapy, 
but possible for only about 15%-20% of PDAC patients at the time of diagnosis 
[508,509]. The shape and size of the primary tumor, cancer stage (usually only 
stages I-II) and the involvement of major local vessels, all play a role in the 
decision to perform surgery [510]. In resectable PDAC, adjuvant therapy can be 
systemic therapy, for reducing metastatic load, or chemoradiotherapy, though 
some studies have disputed the usefulness of adjuvant radiation therapy 
[355,511,512]. Neoadjuvant chemoradiotherapy is sometimes used, though there 
is no consensus for its benefits [355,513]. In locally advanced, unresectable 
pancreatic cancer (stage III), use of radiotherapy may even be questionable, as it 
has given contradicting results [514,515]. Chemotherapy treatment options 
remain, but their results are patient dependent and difficult to predict [355]. In 
metastatic disease (stage IV), patients receive mostly palliative chemotherapy 
[516,517]. Over 90% of diagnosed patients eventually die from the disease; 70% 
from extensive metastases, and 35% of massive primary tumors [459]. Therefore, 
development of biomarkers for early diagnosis and identification of predisposing 





2.4. An overview of gastrointestinal biomarkers 
 
Biomarkers are usually divided into four types: diagnostic, predictive, prognostic 
and therapeutic. Diagnostic markers are used as non-invasive markers to detect 
early disease phases [354]. A prognostic marker should reflect patient survival, 
and ideally provide knowledge of treatment outcome, as well as suggest further 
therapeutic options [518,519]. Predictive biomarkers are used to identify 
subpopulations of patients who would benefit (or not) from a targeted treatment 
[520]. Therapeutic markers are themselves targets for therapy [354]. The aim of 
personalized medicine is to tailor treatment specifically to an individual patient, 
depending on the unique genetic makeup of their tumor(s). For this reason, there 
is an urgent need for identifying new biomarkers for the detection, diagnosis, 
prognostic prediction and evaluation of the viability of therapeutic approaches in 
all three cancer types studied in this thesis. A list of GI-cancer biomarkers is 
gathered in Table 4. 
 
Common biomarkers include nucleic acids, carbohydrates, proteins, lipids, small 
metabolites, and whole tumor cells isolated from body fluids [521]. Serum 
genetic material can also be used for screening for epigenetic changes, including 
aberrant CIMP phenotype, microRNA profile changes and histone modifications, 
which are often present early in carcinogenesis [522]. Circulating tumor cells 
(CTCs) are shed into the bloodstream from solid tumors [523,524], including the 
precursor cells of distant metastases [525,526]. However, while CTCs are not 
present in healthy controls, their presence is not invariably cancer related [527]. 
Prognosticative panels often take into account many and varied biomarkers, 
which help to subgroup patients, and more easily create targeted therapy curated 





Table 4. Biomarkers in use or in development in CRC, GC and PDAC. 
 
D = diagnostic, PRE = predictive, PRO = prognostic, T = therapeutic; 
[354,366,452,521,527-529] 
Biomarker CRC GC PDAC
 18q loss of heterozygosity (LOH) PRO
 BRAF PRO
 Carbohydrate antigen (CA 19-9) PRO D/PRO D/PRO
 Cancer stem cells (CSCs) PRE/PRO D/T
 Carbohydrate antigen (CA 125) D/PRO PRO
 Carbohydrate antigen (CA 50) D/PRO
 Carbohydrate antigen (CA 72-4) D/PRO
 Carcinoembryonic antigen (CEA) PRO D D/PRO
 CDH1 (E-cadherin) PRE
 Chromosomal instability (CIN) PRO
 Circulating tumor cells (CTCs) PRE/PRO D/PRO
 COX-2 T/PRO
 CpG islan methylator phenotype (CIMP) PRO
 Cytotoxi T-lymphosyte antigen 4 (CTLA4) T
 Dihydropyrimidine dehydrogenase (DPD) PRO
 EGFR T PRO
 ERCC1 PRO
 FGFRs T
 Gastric carcinoma-associated antigen MG7-Ag D
 Glurathione S-transferasen P1 (GSTP1) PRO
 HER2 PRE/PRO
 KRAS PRE/PRO
 long non-coding RNAs PRO?
 MET PRE/PRO
 Methylenetetrahydrofolate reductase (MTHFR) PRO
 microRNAs D? D/PRE/PRO
 Microsatellite instability (MSI) PRE/PRO PRO
 MLH1 PRO




 Programmed cell death protein 1 (PD1) T T
 PTEN PRE
 Thymidine phosphorylase (TP) PRO
 Thymidylate syhthetase (TS) PRE
 TIMP PRO
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Recent years have seen an increase in the development of biomarkers for many 
GI cancers. Microsatellite instability is present in 10%-15% CRC, and can be 
used for evaluating disease outcome: patients with MSI-High phenotype have a 
better prognosis [530]. KRAS mutations exist in 20%-40% of CRC [531], and 
the presence of WT KRAS is used as a prognostic marker or to assess therapy 
effectiveness [532-534]. The number of lymphocytes present in tumor periphery 
and in its core are used in determining Immunoscore, a type of prognostic index 
for CRC patients, and a similar method is in development for gastric cancer 
[535,536]. A higher density of lymphocytes translates to a higher score and a 
better prognosis (reviewed in [536]). As a prognostic determinant, the 
Immunoscore was found to be more accurate in stage I-III patients than the 
classical TNM staging [537], and its incorporation into the TNM staging system 
in CRC is being considered [536,538]. However, few predictive markers are 
available to help select therapeutic strategies in CRC [366]. A further problem in 
these studies rises from contradictory results, small cohort sizes and 
inconsistencies in study methods between groups [366]. 
 
Extensively studied biomarkers in gastric cancer include HER-2, E-cadherin, 
FGFR, EGFR, mTOR, HGFR, MET, PD-L1 and TP53 [354]. Emerging 
biomarkers in GC include microRNAs, long noncoding RNAs (lncRNA) and 
matrix metalloproteinases (MMPs) [354]. With the exception of HER-2, there 
are no established predictive biomarkers, and most GC patients do not yet benefit 
from directed molecular therapies [354]. Sialyl Lewis carbohydrate antigen 19-9 
(CA19-9) is a commonly used serum biomarker for PDAC, although it is 
sometimes also expressed in non-cancerous conditions, and not by all pancreatic 
cancer patients [527,539]. Additionally, a part of the population (approximately 
10%) do not produce this antigen [540-543]. The second most common serum 
biomarker in use for PDAC detection is carcinoembryonic antigen (CEA), but 
unlike CA19-9, it is not recommended for use in the US, having low sensitivity 
and specificity [544]. CA125/MUC16 transmembrane glycoprotein 
overexpression is present in many cancers, including PDAC [545,546], and it e.g. 
predicted resectability better than CA19-9 [547]. Circulating exosomes have 
been suggested as diagnostic or prognostic markers [548], such as using 
Glypican-1 (GPC1)-positive exosomes as biomarkers for early PDAC, but this 
research needs further study [549]. Alterations in microRNA (miRNA) profiles 
are prevalent in PDAC, and candidate miRNAs have been suggested for detection 
of early PDAC [550]. There are no specific markers for early diagnosis of 
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pancreatic cancer [339,356], although candidate RNA and protein biomarkers are 
being tested [339]. 
 
Studying protein expression levels from tumor samples is a well-established way 
to identify new biomarkers that can then be developed for future clinical use. 
Tissue microarray blocks (TMA) are used to take small samples from the core of 
a patient tumor sample, which are then treated with immunohistochemistry to 
assess tissue immunoexpression levels of target gene(s). TMA allows processing 
of large patient cohorts in a relatively short time, and the study of multiple 
potential markers from the same tumor sample. When combined with long 
follow-up period and extensive survival data, markers with prognostic potential 
can be identified with relative ease. This method only samples a small part of any 
given tumor, however, and contains little information e.g. about the surrounding 
stroma. This method should therefore be complemented with further molecular 
studies to confirm a potential biomarker role in cancer, such as use of organoid 
models derived from patient tumor samples. In conclusion, extensive work is 






3. Caenorhabditis elegans as a model system in biomedical research 
 
The experiments in the first part of this thesis were performed extensively by 
taking advantage of the well-established model animal, Caenorhabditis elegans. 
Since the work of Dr. Sydney Brenner in the late 1960s, the small (1 mm), 
terrestrial roundworm has developed into a favorite tool in many fields of 
biomedical research, ranging from molecular genetics to large-scale behavioral 
studies. C. elegans is an androdiecious species: individuals are hermaphrodite 
(XX) or male (X0). C. elegans lifespan is relatively short: 3.5 days in 20 °C, 
comprising four larval stages (L1-L4), followed by a young adult stage, where 
egg-laying begins. Hermaphrodite reproduction continues for 1-3 days, and the 
animal will then live a further 1-2 weeks, which has made C. elegans a distinct 
favorite in aging research. During times of stress (e.g. limited food, crowding), 
L1 larvae can develop into an alternate stress-resistant dauer-form, which may 
live several months without nutrition. [553] 
 
Lack of reliable antibodies is one of the few limitations associated with the 
animal, which is why C. elegans is often used together with other, 
complementing model systems; yet, despite its apparent simplicity, several key 
characteristics make it an excellent model animal for multiple types of research. 
The nematodes are easy to handle and cheap to propagate, and strains can be 
frozen and stored in -80 °C or in liquid nitrogen. C. elegans has several different 
tissues, including neurons, muscle and intestine. The animal has approximately 
1000 somatic cells, which follow an invariable and well-recorded pattern of 
division and development. The well-annotated (Wormbase.org) 100 Mb genome 
is organized into six pairs of chromosomes, and has approximately 20 000 genes, 
with thousands of mutants available for researchers. In addition, C. elegans has 
a small mitochondrial genome of 36 genes. Many important signaling pathways 
and homologous disease genes are evolutionarily conserved, making the animal 
a good starting point for varying disease-related research [554]. Further, 
approximately 60%-80% of human genes have C. elegans homologues. Alleles 
are predominantly homozygous, due to repeated selfing of strains. For genetic 
studies, knockdown of individual genes with RNAi is easy to perform, as plasmid 
constructs can be introduced into the bacteria fed directly to the animals. C. 
elegans is also transparent, which allows creation of transgenic lines expressing 
fluorescent marker proteins, e.g. for the study of protein expression or turnover, 
including degradation of proteasomal substrates. [555] 
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AIMS OF THE STUDY 
 
The aim of my thesis was to find new proteasome regulators, and characterize in 
detail their effect on the proteasome. As similar studies have been conventionally 
performed in yeast or by using mammalian cell cultures, the main objective was 
to gather information in vivo in the context of a complex, multicellular organism. 
Identification of the novel proteasome regulator UCHL5/UBH-4 in the first part 
of this thesis was then expanded into an extensive project to study this 
proteasome-associated DUB in gastrointestinal cancers. 
 
More specifically, the aims were: 
 
1. to acquire new information on how the UPS is regulated in vivo on molecular- 
and tissue-specific level, by taking advantage of the well-established model 
system C. elegans, and 
 
2. to investigate the role of the proteasome modulator UCHL5 in different 
gastrointestinal cancers, by comparing UCHL5 immunoexpression with 
clinicopathological factors and patient survival in colorectal cancer, gastric 




PATIENTS, MATERIALS AND METHODS 
 
Materials and methods are described in detail in their respective publications. 
This section provides a summary of the most relevant methods for the thesis. 
 
 





All C. elegans strains were grown under standard laboratory conditions (in 20 °C 
incubator) on normal growth medium (NGM) agar plates with Escheria coli 
OP50-strain as their food source [556]. N2 strain (Bristol isolate) was used as the 
wild-type reference strain in all experiments. The C. elegans strains used in the 
thesis are listed in Table S1 of publication I. Plasmid construction for creation 
of the transgenic lines was performed according to standard cloning techniques, 
and microinjection was used for the generation of transgenic animals, as 
described in [557]. 
 
 
1.2. In vivo UPS-activity reporters and polyubiquitin reporters 
 
Transgenic C. elegans strains used in the thesis are listed in Table S1 of 
publication I. The generation of the UPS-activity reporter is described in detail 
elsewhere ([558], I). Briefly, for the UPS-activity reporter, N2 and other relevant 
C. elegans mutant strains were injected with a plasmid containing either the 
tissue-specific short-lived UPS activity reporter (UbG76V-Dendra2), which is a 
proteasomal substrate, or its long-lived control (Dendra2 alone). These reporters 
can be irrevocably photoconverted with 405 nm from a green to red fluorescent 
conformation, and the variation in the red signal as a function of time can then be 
followed by fluorescent microscopy. The polyubiquitin reporter (Pvha-6::UIM2-
ZsProSensor) is a green fluorescent protein (ZsG), fused with the two UIM-
motifs of 19S Rpn10/S5a subunit, and the C-terminal part of the mouse ornithine 
decarboxylase (MODC), which directs the protein to be degraded by the 
proteasome. The UIM-motifs, however, stabilize the reporter in the presence of 
polyubiquitinated proteins, and the resulting green fluorescent foci can thus be 
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interpreted to reflect polyubiquitinated protein amount in the cell (validation of 
the reporter is described in I). 
 
 
1.3. Lifespan and progeny assays 
 
All lifespan assays were performed at 20 °C. Animals were age-synchronized by 
hypochlorite treatment, which dissolves adults and larvae, but not unhatched 
eggs. The eggs are left to hatch in M9 (22 mM KH2PO4, 42 mM Na2HPO4 and 
86 mM NaCl in MQ) buffer overnight, and then plated on RNAi feeding plates 
as L1 larvae (day 1). The animals were checked daily, and were classified as 
dead, if they failed to react to a tender jab with a platinum worm pick. Animals 
that had internally hatched offspring, died from extruded gonad, crawled off or 
disappeared were censored from the total animal count on the day of occurrence. 
For the progeny counts, age-synchronized animals were plated on RNAi feeding 
plates as one day old (L1 larvae), picked individually to separate plates as three 
days old (L4 larvae), and moved daily to fresh plates to avoid crowding. Total 
viable offspring per animal was then counted. The offspring of animals that had 
internally hatched offspring, died from extruded gonad, crawled off or 
disappeared were censored from the experiments. 
 
 
1.4. Mammalian cell culturing 
 
Human osteosarcoma (U-2 OS) cells were cultured using Dulbecco’s modified 
Eagle’s medium including 15% fetal bovine serum (Gibco). FlexiTube 
GeneSolution for uchl5 and AllStars Negative Control siRNA with HiPerFect 
Transfection Reagent were added to the cells for siRNA (small interfering RNA), 
all acquired from Qiagen. Fugene 6 (Roche) was used to transfect pEGFP-C1-
Ataxin3Q28 (Addgene plasmid 22122), pEGFG-C1-Ataxin3Q84 (Addgene 
plasmid 22123) [559] and UbG76V-GFP (Addgene plasmid 11941) [560] 
expression vectors. Cells were fixed in 3.5% paraformaldehyde in phosphate 
buffered saline (PBS). PI(3)K inhibition was performed with 7 h treatment with 






1.5. Microscopy and image analysis 
 
The transgenic UbG76V-Dendra2 and Dendra2 animals were imaged at four days 
old (young adult stage). The animals were mounted on a small agarose pad on a 
glass slide and immobilized using 0.5 mM levamisole diluted in M9 buffer. In 
between imaging, animals were allowed to recover freely on feeding plates. A 
motorized Zeiss Axio Observer Z1 inverted microscope with LSM 5 Live line-
scanner was used for imaging. LSM AIM software Rel. 4.2. was used. A 63x 1.4 
NA plan-apochromat objective was used for acquiring images. Zeiss LSM image 
Examiner version 4.2 was utilized for analyzing the fluorescence intensities of 
the images. Transgenic polyubiquitin reporter (Pvha-6::UIM2-ZsProSensor) 
animals were imaged as six days old, and strains carrying transcriptional 
reporters were imaged as four days old (young adult stage). These strains were 
imaged with Axioplan 2 microscope with 10x 0.3 NA objective. The fluorescence 
intensity of polyubiquitin reporter animals was quantified using the free image 
quantification software Fiji. Immunostained polyubiquitin reporter animals were 
imaged with a motorized Zeiss AxioVert 200M inverted confocal microscope 
with LSM 510 point scanner. LSM software release 3.2 and 63x 1.4 NA plan-
apochromat objective were used. uchl5 transfected U-2 OS cells and 
ataxin3(Q28)-GFP or ataxin3(Q84)-GFP expressing constructs were imaged 
with Zeiss Axioplan 2 microscope with 20x 0.5 NA objective. Cells expressing 
UbG76V-GFP treated with siRNA were imaged with 10x 0.3 NA objective. 
Fluorescence intensities and aggregate counts were analyzed in a pipeline created 
in the Anduril analysis framework [561]. 
 
 
2. Biochemical methods used in I 
 
 
2.1. Immunofluorescence in C. elegans 
 
A mixed population of animals of varying age expressing the intestinal PVha-
6::UIM2-ZsProSensor reporter was fixed and permeabilized, according to the 
protocol described by Finney and Ruvkun, 1990 [562]. Polyubiquitinated proteins 
were visualized with the FK1 antibody (Enzo Life Sciences) with an Alexa Fluor 




2.2. RNA interference (RNAi) in C. elegans by feeding 
 
Unless otherwise stated, RNAi was performed according to the standard feeding 
protocol described by Timmons et al., 2001 [563]. The normal food source of the 
animals is replaced by bacteria containing a plasmid for the gene of interest, or 
only the empty control vector. Experiments utilizing RNAi clones from the J. 
Ahringer library used the HT115 E. coli strain carrying an empty pL4440 
expression vector as control. The rpn-2 RNAi (C23G10.4, J. Ahringer library) 
RNAi on daf-2(e1370) mutants carrying intestinal UbG76V-Dendra2 was started 
at two days old (L3 larvae), two days before imaging. The rpn-2 RNAi for RNAi 
sensitive rrf-3(pk1426) animals was started at three days old (L4 larvae), and 
animals were harvested two days later for proteasome in-gel activity assays. The 
rpn-2 RNAi on animals expressing polyubiquitin reporter in the intestine was 
started at three days old (L4 larvae), and the animals were imaged after three 
days. 
 
Bacteria carrying empty RNAi vector (pL4440) were used to dilute ubh-4 RNAi 
bacteria for relevant experiments. RNAi against ubh-4 and lgg-1 (C08B11.7 and 
C32D5.9, J. Ahringer library) were started at one day old (L1 larvae) for imaging. 
ubh-4 RNAi was initiated at the same stage also in proteasome in-gel activity 
assays, lifespan experiments and progeny counts. The RNAi constructs for daf-
16 (pAD43) and pAD12 (control) were generous gifts of Dr. Andrew Dillin. 
Induction of the plasmids were achieved by adding 10m isopropyl b-D-1-
thiogalactopyranoside (IPTG) in the growth media. IPTG was added to a final 
concentration of 20 mM before seeding the bacteria on NGM agar plates 
(containing 100 µg/ml Amp + 12,5 µg /ml Tet + 0,4 mM IPTG). L4440-daf-16a 
(plasmid 31503) and L4440-daf-16 df (plasmid 31505) RNAi expression vectors 
[564] were purchased from Addgene. RNAi against daf-16 was initiated at one 
day old (L1 larvae) in all experiments, and all animals were imaged at four days 





Animals from three large agar plates were collected into M9 buffer into a final 
volume of 1.5 ml for UBH-4 immunoprecipitation. Dounce homogenizer (7 ml, 
tight pestle) was used for animal lysis in native-gel lysis buffer, using 
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approximately 150 pushes with the Dounce [565]. Following product 
instructions, His-tag immunoprecipitation was performed with 50 µl of Protino 




2.4. Native proteasome and deubiquitinase activity in-gel assays 
 
Four days old (young adult) animals age-synchronized with hypochlorite 
treatment were collected in M9 buffer and frozen in -80 °C overnight. A Dounce 
homogenizer was used for lysing the collected samples in native-gel lysis buffer 
[565]. In-gel proteasome activity assay used suc-LLVY-AMC (Bachem) as the 
substrate. Colloidial Blue Staining Kit (Invitrogen) was used for Coomassie 
staining to assess sample loading. Deubiquitinating assay was performed in 
similar manner as proteasome in-gel activity assay, but the substrate was 
substituted with ub-AMC (Boston Biochem). Photoshop 9.0 (Adobe Systems) 
was used for adjusting signal levels and Fiji was used for quantification.  
 
 
2.5. Western blotting 
 
Young adult animals age-synchronized with hypochlorite treatment were 
collected in M9 buffer and frozen in -80 °C overnight. Samples were changed 
into Laemmli sample buffer [566] and lysed by alternate boiling and freezing, or 
by sonication in lysis buffer (50 mM Hepes (pH 7.4); 150 mM NaCl, 5 mM 
EDTA; 20 mM NEM and protease inhibitor tablet (Roche)), or with using native-
gel sample lysis method. 7.5% and 10% polyacrylamide gel were used for sample 
separation. The gels were blotted onto nitrocellulose membrane with a semi-dry 
blotting system (BioRad Laboratories).  
 
Antibodies used were: anti-a-tubulin antibody (Sigma), FK1 antibody for 
polyubiquitinated proteins (Enzo Life Sciences), proteasome 20S a1,2,3,5,6,7 
antibody (Enzo Life Sciences), Anti-His antibody (Qiagen) and anti-HA antibody 
(Covance). Streptavidin-HRP conjugate (Dako) was used in blotting. Photoshop 
9.0 (Adobe Systems) was used to adjust Western blot signal levels, which were 




2.6. Quantitative real-time PCR (qPCR) 
 
Age-synchronized four days old (young adult) animals were collected and used 
for RNA extraction with the NucleoSpin RNA II kit (Macherey-Nagel) or 
GeneJet RNA Purification Kit (Fermentas). Maxima First Strand cDNA 
Synthesis kit for RT-qPCR was used for cDNA synthesis. Quantitative real-time 
PCR was performed with Maxima® SYBR Green/ROX qPCR Master Mix (2x) 
(Fermentas), using LightCycler 480 qPCR machine (Roche). Table 5 lists the 
oligos used in qPCR analyses. 
 
 
Table 5. qPCR oligos. 
Gene (C. elegans) Forward  Reverse  
 ubh-4   acttgttccaaaccgcaaac   tttccttgcggtacatttcc  
 act-1   tcggtatgggacagaaggac   catcccagttggtgacgata  
 cdc-42    ctgctggacaggaagattacg   ctcggacattctcgaatgaag  
 pmp-3   gttcccgtgttcatcactcat   acaccgtcgagaagctgtaga  
 sod-3   ggagttctcgccgtccg   gtcgaatgggagatctgggag  
 hsp-12.6   tggagttgtcaatgtcctcg   gacttcaatctcttttgggagg  
 mtl-1   agtgtgactgcaaaaacaagcaa   tccactgcattcacatttgtctc   
 fat-7   atagtgtggcgtaacgtggc   tagagagcaaatgagaagacg  
 aft-5   ccatcaatcttatcaacagcatcat   ctggtggaaccgaagtg  
 haf-7   gacgtggaaaagctgagagg   gcagggaaaatgtgaggaaa  
 gst-10   gtctaccacgttttggatgc   actttgtcggcctttctctt  
 gst-4   cccattttacaagtcgatgg   cttcctctgcagtttttcca  
 gcs-1   aatcgattcctttggagacc   atgtttgcctcgacaatgtt  
 rpn-6.1   gccgatttgattcgtgaact   caccagtgagagaagcacga  
Gene (human) Forward  Reverse  
 uchl5   gccagttcatgggttaattttt   atcgtgtcaagtcgggagtc  
 gapdh   acccagaagactgtggatgg   ttcagctcagggatgacctt  












The patient cohorts (including the relevant ethical permit numbers) are described 
in more detail in their respective publications (II-IV). 
 
3.1.1. Patients in publication II 
 
The patient cohort comprised 154 PDAC patients who underwent elective 
surgery between 2000-2011 at the Department of Surgery, Helsinki University 
Hospital, Finland. No other variants of exocrine pancreatic cancer were included 
in the study. Median age of patients was 64 (range 39-83), with a median follow-
up of 2.0 (range 0.2-13.1) years. Patient records were used to gather clinical data, 
survival data was provided by the Finnish Population Registry, and cause of death 
by Statistics Finland [567-569]. 
 
3.1.2. Patients in publication III 
 
The patient cohort comprised of 840 CRC patients treated between 1983-2001 at 
the Department of Surgery, Helsinki University Hospital, Finland. Patient 
median age was 66, with a median follow-up of 5.1 years (range 0-25.8). Patient 
records were used to gather clinical data, follow-up data was provided by the 
Finnish Population Register Centre, and cause of death was provided by Statistics 
Finland. [570] 
 
3.1.3. Patients in publication IV 
 
The patient cohort comprised of 650 gastric cancer patients treated between 
1983-2009 at the Department of Surgery, Helsinki University Hospital, Finland. 
Patient median age was 66.9 (interquartile range 57.0-75.0), with a median 
follow-up time of 1.6 (interquartile range 0.6-4.7) years. Patient records were 
used to gather clinical data, while survival data was acquired from the Population 





3.2. Preparation of tumor tissue specimens 
 
Tumor samples from the archives of the Department of Pathology, Helsinki 
University Hospital were formalin-fixed and paraffin-embedded. An experienced 
pathologist marked representative tumor areas on hematoxylin- and eosin-stained 
tumor slides (II-IV), and further re-confirmed PDAC histopathological diagnosis 
(II). A semiautomatic tissue microarray instrument (TMA) (Beecher 
Instruments, Silver Spring, MD) was used to acquire and mount either three 0.6 
mm (IV) punches, and six (II), three (III) or four (IV) 1.0 mm punches from 
each donor block on the recipient TMA blocks. 
 
 
3.3. Antibodies for immunohistochemistry 
 
Rabbit anti-UCHL5 antibody (Sigma Aldrich HPA005908) was used for 
immunohistochemical stainings (II-IV). A small subset of samples was validated 
with a second anti-UCHL5 antibody (Santa Cruz sc-271002 (II-IV)). 
Additionally, a third anti-UCHL5 antibody (Sigma Aldrich SAB1400553) was 





TMA- and tissue blocks were freshly cut into 4 µm sections. Deparaffinization 
of the slides was performed with xylene, and rehydration achieved through a 
decreasing ethanol and distilled water series. For antigen retrieval, slides were 
treated in a PreTreatment module (Lab Vision Corp., Fremont, CA, USA) in Tris-
HCl (pH 8.5) buffer for 20 min. at 98°C. Autostainer 480 (Lab Vision) by Dako 
REAL EnVision Detection system, Peroxidase/DAB+, Rabbit/Mouse (Dako, 
Glostrup, Denmark) was used for staining of the sections. Primary antibody was 
incubated for 1 hour at room temperature. 
 
 
3.5. Sample scoring and imaging 
 
UCHL5 expression was scored according to tumor-staining intensity as 0 
(undetectable staining, negative), 1 (low staining), 2 (moderate staining), or 3 
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(strong staining) (II-IV). In PDAC, nuclear intensity was scored separately from 
cytoplasmic staining according to the proportion of positive nuclei present in the 
tumor tissue: 0%-10% positive nuclei scored as 0, 11%-40% as 1, 41%-75% as 
2, and 76%-100% as 3 (II). Scoring was performed independently without 
knowledge of patient identity or disease outcome, first by one researcher, and 
then confirmed by an experienced pathologist. Any differences in sample scoring 
were discussed until a consensus was reached. Randomly chosen staining 
samples were chosen for representative images (II-IV). 
 
 
3.6. Statistical analysis 
 
Similar methods were used in all three clinical papers (II-IV) for statistical 
analysis, and in all three a large part of the analysis was performed by the same 
biostatistician. However, as in all three studied cancer types UCHL5 
immunoexpression was handled slightly differently after scoring, and as all 
cancers record varying relevant clinicopathological traits, the statistical analysis 
performed on the material are here described separately. 
 
II: UCHL5 expression was dichotomized for statistical purposes. Cytoplasmic 
UCHL5 immunoexpression was divided into low (scores 0-1) and high (scores 
2-3) staining, and nuclear immunoexpression into either negative (< 10% nuclear 
positivity, score 0) or positive (> 10%, scores 1-3) staining. Median score of each 
patient was used in further analysis, because expression values in pancreatic 
tumor tissue often show great variation. Fisher’s exact test and linear by linear 
association was used to evaluate association of UCHL5 expression and 
clinicopathological parameters. The Kaplan-Meier method was used for survival 
analysis, and groups were compared with the Breslow test. Uni- and multivariate 
survival analysis was analyzed with the Cox regression proportional hazard 
model adjusted for age, gender, stage, metastasized lymph-node ratio (LNR) 
≥/<20% (cut-off ≥/<20%), and postoperative adjuvant therapy. A combination 
variable was generated for multivariate analyses because stage and LNR are 
internally correlated. Interaction terms were considered. The assumption of 
constant hazard ratios over time for the Cox model was tested. For each testable 
variable at a time, a time-dependent covariate was included separately. All 
variables fulfilled the assumption. A p value of less than 0.05 was considered 
significant, with all tests two-sided. Analysis was performed on SPSS version 
68 
 
24.0 (IBM SPSS Statistics, version 24.0 for Mac; SPSS, Inc., Chicago, IL, USA, 
an IBM Company). 
 
III: The four scoring categories (0-3) of UCHL5 immunoexpression were kept 
separate for statistical analysis. Fisher’s exact test and linear by linear association 
test (with Monte Carlo estimation of exact p values) was used to evaluate 
association of UCHL5 expression and clinicopathological parameters. 
Cumulative survival was evaluated by Kaplan-Meier survival analysis, and 
differences between groups were compared with the log rank-test. A post-hoc 
analysis with individually comparing UCHL5 expression levels 0-2 to the high 
expression level (3) one by one was used, if the overall survival comparison 
between expression levels of UCHL5 was significant. The Šidác correction was 
applied to multiple comparisons. The 5- and 10-year survival rates and mean 
survival times were calculated with confidence intervals (CI, 95%). For model 
uni- and multivariate analysis, Cox proportional hazard regression was 
performed on survival data. A time-dependent variable for each testable variable 
was added to test the Cox model assumption of constant hazard ratios over time. 
Hazard ratios of Dukes D class and differentiation status were analyzed in two 
time-periods with the time-dependent Cox model to fulfil the Cox model 
assumption. Interactions were considered, but no significant interaction emerged. 
A p value less than 0.05 was considered significant, and two-tailed tests were 
used. Statistical analysis was performed with IBM SPSS statistical package 
version 22 (IBM, New York, NY, USA) and SAS version 9.4 (SAS Institute Inc., 
Cary, NC, USA). 
 
IV: UCHL5 expression was dichotomized for statistical purposes into either 
negative (score 0) or positive (scores 1-3), and the maximum score was used in 
the statistical analysis. Fisher’s exact test and linear by linear association test 
(with Monte Carlo estimation of exact p values) was used to evaluate association 
of UCHL5 expression and clinicopathological parameters. Cumulative survival 
was evaluated with Kaplan-Meier survival analysis, and differences between 
groups were compared with the log rank-test. Survival rates were calculated with 
exact 95% confidence intervals (CI). The Cox regression proportional hazard 
model was used for uni- and multivariable survival analysis, and multivariable 
model was adjusted for age, gender, stage and tumor size (≥ 5 cm vs. <5 cm). 
The assumption of constant hazard ratios over time for the Cox model was tested. 
For each testable variable, a time-dependent covariate was included separately 
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one at a time. Except for one multivariable model, all variables fulfilled the 
assumption. Interaction terms were considered. A p value of less than 0.05 was 
considered significant, and two-tailed tests were used. Statistical analyses were 
performed with SPSS version 24.0 (IBM SPSS Statistics, version 24.0; SPSS, 
Inc., Chicago, IL, USA, an IBM Company, and with SAS version 9.4 (SAS 




RESULTS AND DISCUSSION 
 
 
1. Proteasome-associated deubiquitinase UCHL5/UBH-4 is a modulator of 
proteasome activity in C. elegans and human cancer cells (I) 
 
 
1.1. Insulin/IGF-1 signaling regulates proteasome activity in a tissue-specific 
manner through DAF-16/FOXO in C. elegans 
 
In a previous work from our 
laboratory, a tissue-specific change 
in proteasome activity was observed 
in aging C. elegans [558]. The 
degradation of the photoconvertible 
UPS activity reporter (UbG76V-
Dendra2, see Methods 1.2.) was 
diminished in the neuronal dorso-
rectal ganglion, but not in the body-
wall muscle cells of one week old 
animals. To explain this 
observation, we decided to study the 
potential role of Insulin/ Insulin-like 
growth factor 1 (IGF-1) signaling 
(IIS) in modulation of proteasome 
activity in C. elegans. IIS is a well-
established aging-regulatory 
pathway, modulating lifespan and 
various stress responses in C. 
elegans and higher organisms 
[257,573]. Figure 4 illustrates a 
simplified version of the IIS 
pathway, and names some of the key members in humans and C. elegans. The 
IIS cell-surface receptor in C. elegans is DAF-2. Long-lived daf-2(e1370) null-
mutants exhibit reduced IIS, resulting in approximately two-fold expansion in 
lifespan and increased stress resistance [574-576]. IIS negatively regulates the 
transcription factors DAF-16/FOXO and SKN-1/Nrf [577-580]. Under reduced 
Figure 4. Insulin/IGF-1 signaling 
(IIS) in C. elegans and humans. 
Modified from Sun et al., 2017. [581] 
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IIS, DAF-16/FOXO becomes localized to the nucleus and constitutively active 
[258]. DAF-16 is also required for the lifespan extension seen in daf-2(e1370) 
mutants, and DAF-16 null mutants have a shortened lifespan [579, 581]. 
Although many studies have linked IIS to UPS regulation (e.g. [279,297]), it was 
unknown whether the proteasome itself is regulated by IIS. 
 
Using our UPS-activity reporter, we observed an increase in its degradation in 
both the intestine (I: Figure 1A and 1B) and body-wall muscle cells (I: Figure 
1D) of long-lived daf-2 mutant animals. In the intestine, this increase in 
proteasomal activity was found to be DAF-16 dependent, where the UPS-activity 
reporter degradation in short-lived daf-16;daf-2 double mutants was comparable 
to wild type animals (I: Figure 1A and 1B). Intriguingly, different daf-16 
mutants exhibited ambiguous results in body-wall muscle cells in degradation of 
the UPS-activity reporter. Altogether eight DAF-16 isoforms have been 
described in C. elegans, which are expressed differently in various tissues, and 
convey different functions [582]. The short-lived DAF-16 mutants used in (I) 
were daf-16(m26), which lacks five isoforms, and the DAF-16 null-mutants daf-
16(mgDf47) and daf-16(mgDf50). Short-lived daf-16(m26) mutants displayed 
similar reporter degradation rate as the long-lived daf-2 mutants (I: Figure 1D). 
In contrast, short-lived daf-16(mgDf50) null-mutants had a reporter degradation 
rate similar to that of wild type animals (I: Figure 1D). Further, the short-lived 
daf-16(m26);daf-2(1370) double mutants exhibited UPS activity that was not 
significantly different from either daf-2(1370), or wild type animals, but falling 
somewhere in between the two (I: Figure 1D). Last, in the second short-lived 
daf-16(mgDf47);daf-2(1370) double mutant, UPS-activity reporter degradation 
was again comparable to degradation rate exhibited by daf-2(1370) mutants (I: 
Figure 1D). Taken together, it appears that in C. elegans body-wall muscle cells, 
IIS regulates UPS-activity through different DAF-16 isoforms than in the 
intestine, and in addition through other yet unidentified factor(s). This creates 
another interesting level into the UPS-activity regulation mediated by IIS. 
 
As it is possible that the degradation of the UPS-activity reporter is affected by 
specific E3 ubiquitin ligases, we used our second in vivo reporter 
(ZsProSensor::UIM2, see Methods 1.2) that binds to endogenous 
polyubiquitinated proteins to complement the results. RNAi against daf-16 
increased reporter amount in the intestine of long-lived daf-2 animals, but not in 
the wild type background (I: Figure 2). This confirmed the importance of DAF-
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16 for activating proteasomal degradation in the intestine. Downregulation of 
daf-16 with RNAi in the long-lived daf-2 mutants is to some extent analogous to 
the inactive DAF-16 state present in the wild type background, which could cause 
accumulation of polyubiquitinated proteins reflected by the reporter. Further, a 
biochemical approach using in-gel proteasome activity assay (protocol according 
to [565]) also showed increased proteasome catalytic activity under reduced IIS 
in a DAF-16 dependent manner (I: Figure 3A and 3B). In the long-lived daf-2 
mutants, there was an increase in the degradation of the 20S CP substrate (suc-
LLVY-AMC), whereas the short-lived daf-16 and daf-16;daf-2 double mutants 
exhibited activity closer to wild type animals (I: Figure 3A and 3B). However, 
this assay is not tissue-specific, as it uses native proteasome complexes isolated 
from whole animal-lysates. 
 
Remarkably, though we observed increase in degradation in the long-lived daf-2 
mutants at multiple fronts, we could detect no difference in the amount of 
proteasome a-subunits (I: Figure 3C and Figure 3D). Western blot performed 
from whole animal lysates displayed no significant differences in proteasome 
amounts between long-lived daf-2 mutants, short-lived daf-16 mutants, nor short-
lived daf-16;daf-2 double mutants, when compared to wild type animals (I: 
Figure 3C and Figure 3D). In support of our observation, neither gene 
expression profiling or microarray proteome analysis with mass spectrometry has 
detected DAF-16-induced proteasome subunit expression in long-lived daf-2 
mutants [583-585]. Further, in a recent study from our laboratory, using formalin-
fixed, paraffin-embedded C. elegans sections, no difference in proteasome tissue 
immunoexpression was seen in the long-lived daf-2 mutants, compared to wild 
type animals [586]. This suggests that the DAF-16-mediated increase in UPS 
activity was not a result of direct changes in proteasome abundance. 
 
 
1.2. The proteasome-associated deubiquitinase UBH-4 is a DAF-16 target gene 
 
As there was no detectable difference in proteasome amounts in the long-lived 
daf-2 mutants, we postulated that there could be differences in proteasome 
composition. Mass spectrometry (LC-MS/MS) analysis was performed by an 
outside source on proteasome complexes isolated in native gel, using samples 
from both long-lived daf-2 mutants and wild type animals. The most notable 
difference between the samples was the presence of the proteasome-associated 
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DUB UBH-4 in wild type animals, absent from daf-2 mutants (I: 
Supplementary Table 3). The association between 19S subunit RPN-13 and 
UBH-4 previously identified in vitro for C. elegans [587] was confirmed in vivo 
by immunoprecipitation (I: Figure 4A). UBH-4 DUB-activity in C. elegans was 
also corroborated using native in-gel assay, where knockdown of ubh-4 with 
RNAi lead to decreased degradation of the DUB-specific ub-AMC substrate (I: 
Figure 4B). Using transcriptional reporter animals, we observed that wild type 
animals expressed UBH-4 in all tissues, and most notably in the intestine (I: 
Figure 5A, the first row of panels from the left). In contrast, the intestine of long-
lived daf-2 mutants was conspicuously lacking in UBH-4 expression (I: Figure 
5A, the second row of panels from the left). Both short-lived daf-16 mutants and 
daf-16;daf-2 double mutants had a similar expression pattern with wild type 
animals (I: Figure 5A, the four panels on the right). One canonical DAF-16 
binding site was found on the ubh-4 promoter region. Mutation of this binding 
site re-established UBH-4 transcriptional reporter expression in the intestine of 
long-lived daf-2 mutants (I: Figure 5B). Together, this supports a role for DAF-




1.3. UBH-4 modulates proteasome activity and life history traits in C. elegans 
 
Lower UBH-4 expression and higher proteasome activity were observed in the 
long-lived daf-2 mutants most prominently in the intestine. The lifespan 
expansion exhibited by these animals is also significantly dependent on DAF-16 
activity in the intestine [588]. Therefore, we postulated that UBH-4 functions as 
a proteasome inhibitor under normal IIS, probably in a tissue-specific manner. A 
similar inhibitory role has already been established for USP14/Ubp6 in delaying 
proteasomal degradation [218,220,589]. It is also known that the mammalian 
orthologue UCHL5 trims substrate ubiquitin chains, at times saving them from 
degradation [219,220,590]. When measured by qPCR, long-lived daf-2 mutants 
exhibited approximately 20% lower ubh-4 messenger RNA (mRNA) level than 
wild type animals (I: Figure 5C). Both short-lived daf-16 and short-lived daf-
16;daf-2 double mutants had ubh-4 mRNA level comparable with wild type 
animals, supporting our conclusion that DAF-16 negatively regulates UBH-4 
expression. Hoping to artificially mimic the reduced UBH-4 levels present in daf-
2 mutants, we mixed ubh-4 RNAi with control bacteria containing only the empty 
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pL4440 vector. As a result, ubh-4 RNAi diluted to 1% concentration with the 
control bacteria induced a knock down of UBH-4 levels to 80% in wild type 
animals (I: Figure 5D). 
 
We performed a series of experiments with both undiluted and diluted (1%) ubh-
4 RNAi. In the intestine, we observed higher UPS-activity reporter degradation 
following both undiluted and diluted ubh-4 RNAi (I: Figure 6A). Similarly, the 
intestinal polyubiquitin reporter displayed decreased accumulation of 
polyubiquitinated proteins after both undiluted and diluted ubh-4 RNAi (I: 
Figure 6C). The in-gel activity assay performed from whole animal lysates 
showed an increase in proteasome catalytic activity after undiluted ubh-4 RNAi 
(I: Figure 6D). In contrast, undiluted ubh-4 RNAi decreased degradation of the 
UPS-activity reporter compared to the wild type in body-wall muscle cells, and 
reporter degradation after diluted ubh-4 RNAi was comparable with the wild type 
in these animals (I: Figure 6B). Further, undiluted ubh-4 RNAi also increased 
accumulation of polyubiquitinated substrates by Western blot in whole animal 
lysates (I: Figure 4C and Figure 4D). Taken together, UBH-4 appears to tissue-
specifically inhibit the proteasome. Following ubh-4 RNAi, polyubiquitinated 
substrates are accumulated in some tissue(s), which exhibits as accumulation of 
proteasome substrates on organismal level. It is possible that UHB-4 levels 
fluctuate along a dynamic range. Too high UBH-4 level inhibits the proteasome 
in disproportionate amounts, whereas too low UBH-4 level is in other ways 
problematic. This could be caused in part by the role of UBH-4 in ubiquitin-chain 
trimming [219], which could assist in keeping undegradable substrates from 
becoming stalled on the proteasome. Conversely, UBH-4 could also save lightly 
ubiquitinated substrates from being destroyed, while promoting the degradation 
of more heavily ubiquitinated proteins. The optimal range of UBH-4 expression 
is almost certainly tissue-specific, and probably alters in response to prevailing 
cellular conditions, e.g. reduced IIS. Additionally, the decreased degradation of 
the UPS activity reporter observed in body-wall muscle cells after undiluted ubh-
4 RNAi could also be caused by a decline in overall physiology, as the animals 
appeared outwardly unwell during imaging.  
 
We were also interested in how UBH-4 might affect different C. elegans life 
history traits, such as lifespan and progeny amounts. A previous genome-wide 
RNAi screen had shown that ubh-4 RNAi slightly increases lifespan [591]. 
However, undiluted ubh-4 RNAi resulted in consistent lifespan reduction of the 
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RNAi sensitive rrf-3(pk1426) mutant used as the wild type in our lifespan 
experiments (I: Figure 6F and Supplementary Table 4). The different result 
could be dependent on either RNAi efficacy, or the different temperature used in 
the experiments, which in the case of Hamilton et al. constitutes a mild heat stress 
for the animals (25 °C compared to 20 °C used in our experiments) [591]. In 
contrast, diluted ubh-4 RNAi produced a slight but consistent increase in lifespan 
of the rrf-3 mutants (I: Figure 6F and Supplementary Table 4). A similar effect 
was also evident in progeny amounts: undiluted ubh-4 RNAi decreased offspring 
amounts, whereas diluted ubh-4 RNAi had no effect (I: Supplementary Table 
5). 
 
In the long-lived daf-2 mutants and the short-lived daf-16 mutants, both undiluted 
and diluted ubh-4 RNAi had no effect on animal lifespan (I: Figure 6F and 
Supplementary Table 4). Further, intestinal overexpression of UBH-4 slightly 
decreased daf-2 mutant lifespan (I: Figure 6H and Supplementary Table 4). 
Taken together, the results indicate that for daf-2 mutants, the decrease in UBH-
4 expression is important for at least a part of the lifespan extension normally 
observed in these animals. On the other hand, the normally observed levels of 
UBH-4 in the daf-2 mutants may already optimal, so further knockdown of ubh-
4 by RNAi has no cumulative positive effect on their lifespan. In addition, 
activation of other DAF-16 target gene(s) are likely needed for the diluted ubh-4 
RNAi-mediated lifespan extension, as there was no change in lifespan in the 
short-lived daf-16 mutants (I: Figure 6F and Supplementary Table 4). It 
appears that correct level of UBH-4 expression is important for achieving the 
observed slight lifespan extension in the RNAi sensitive rrf-3 animals. This 
tissue-specificity and balance in the levels of IIS signaling needed for increased 
lifespan and proteostasis has been described elsewhere [260]. The apparent 
existence of tissue-specific optimal level of UBH-4 beneficial for the organism 
implied by our results support this finding. 
 
 
1.4. Knockdown of uchl5 promotes degradation in mammalian cell lines 
 
Our promising results with UBH-4 prompted interest in its mammalian 
orthologue, UCHL5. We inhibited PI(3)K, an important component of the IIS 
pathway, in human osteosarcoma cells (U-2 OS), thus causing an approximately 
30% knockdown of uchl5 mRNA levels (I: Figure 7A). Therefore, IIS appears 
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to regulate human UCHL5 in a similar way that UBH-4 is regulated in C. elegans. 
The degradation of UPS-activity reporter UbG76V-GFP was also increased 
following uchl5 siRNA-induced knockdown, demonstrating that UCHL5 
regulates proteasome activity also in U-2 OS cells (I: Figure 7B and 
Supplementary Figure 7A). Finally, we observed increased degradation of 
ataxin3(Q28) and the proteotoxic ataxin3(Q84) following uchl5 siRNA (I: 
Figure 7C and Supplementary Figure 7). UCHL5 could therefore have clinical 
relevance as a therapeutic target in protein aggregate-diseases, as a decrease in 




2. UCHL5 is a prognostic marker in three gastrointestinal cancers (II-IV) 
 
Following our discovery that uchl5 downregulation increases degradation of 
proteotoxic proteins in human cancer cells (I: Figure 7C and Supplementary 
Figure 7), we became curious of the role of this DUB in different gastrointestinal 
cancers. Our interest was further increased by the fact that the effects of UBH-4 
were particularly striking in the C. elegans intestine (I: Figure 6A and 6C). 
UCHL5 levels are also reported to be elevated in e.g. breast, vulva and 
parathyroid cancers, and UCHL5 exhibited increased activity in cervical cancer 
[311]. For this thesis, UCHL5 immunoexpression was studied from patient tumor 
samples in three different gastrointestinal cancers: pancreatic ductal 
adenocarcinoma (PDAC, II), colorectal cancer (CRC, III) and gastric cancer 
(GC, IV). UCHL5 tumor expression, in association with clinicopathological 
variables and patient survival, were studied from all three cancer types, with 
promising results and with possible clinical potential. 
 
 
2.1. UCHL5 tumor expression pattern varies depending on tissue of origin 
 
UCHL5 tumor expression pattern, as measured with immunohistochemistry, was 
uniform and widespread throughout the tumor tissue cytoplasm in all three 
cancers, when present (II-IV: Figure 1). Interestingly, UCHL5 tumor expression 
pattern and levels showed a degree of tissue-specific variation in the studied 
cancers. Human Protein Atlas reports that UCHL5 tumor expression levels are 
predominantly moderate to low in all three studied cancer types [592]. 
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Accordingly, in CRC and GC, moderate to low expression values comprised 79% 
and 69% of samples, respectively (III and IV). Further, in CRC and GC, only 
cytoplasmic staining was evaluated. In these two cancers, nuclear staining 
appeared to be either low, or masked by the ubiquitous cytoplasmic staining. This 
made it difficult to reliably assess if and to what degree nuclear staining was 
present in a majority of the samples, and therefore only cytoplasmic staining was 
scored. 
 
In stark contrast, the majority (94.7%) of samples in PDAC were UCHL5 
negative in the cytoplasm, or exhibited only low UCHL5 tumor staining (II: 
Figure 1A and 1B).  Conversely, the amount of UCHL5 positive nuclei showed 
high variation in PDAC tumor samples, or were possible to more accurately 
assess in the absence of potentially obscuring cytoplasmic staining. Positive 
(11%-100% positive nuclei) nuclear UCHL5 staining was scored in 51.7% of the 
samples, although only 5.9% exhibited high (76%-100% positive nuclei) UCHL5 
expression (II: Table 1). Meanwhile, in the tumor-adjacent normal-appearing 
tissue, UCHL5 expression was predominantly low or negative in all three studied 
cancers (data not shown). In support of these findings, we observed tissue-
specific variation also in C. elegans UBH-4 expression (I: Figure 5A and 5B). 
Therefore, the possibly context-dependent and dynamic range of UCHL5 levels 
might reflect tissue-specific differences in UCHL5-mediated effects also in 
mammalian tissues. 
 
In both GC and PDAC, UCHL5 tumor expression was dichotomized for further 
statistical analysis after scoring. In GC (IV), comparisons were made between 
UCHL5 tumor immunopositivity and negativity (0 vs. 3). In PDAC (II), nuclear 
UCHL5 staining was divided into positivity and negativity (0 vs. 3), whereas 
cytoplasmic staining was divided into low (scores 0-1) and high (scores 2-3). In 
contrast, in CRC (III) UCHL5 staining intensities associated with survival in an 
unconventional order, so that both high and negative UCHL5 tumor expression 
linked to increased survival. For this reason, the four scoring categories were kept 







2.2. UCHL5 tumor expression correlates with cancer-specific survival in 
colorectal cancer, gastric cancer and pancreatic ductal adenocarcinoma 
 
Significant cancer-specific survival (CSS) differences correlating with UCHL5 
tumor expression were found in the whole patient cohort only in PDAC, where 
both high cytoplasmic (p = 0.034) and positive nuclear (p = 0.005) expression 
associated with better prognosis (II: Figure 2A and 2B). However, though high 
cytoplasmic staining correlated with increased survival in PDAC, patients 
exhibiting this level of UCHL5 expression constituted only 8 patients (5.3% of 
the patient cohort). Corroboration of this result in other sample sets is required 
for making informed deductions about the role of cytoplasmic UCHL5 
expression in PDAC. Additional subgroup analysis in PDAC patients revealed 
that distinct survival benefits associated with positive UCHL5 nuclear 
expression, e.g. in patients with regional disease (stages IIB-III, p = 0.007) and 
65 years or older (p = 0.001) (II: Figure 3A and 3B). 
 
Importantly, subgroup analysis revealed that UCHL5 tumor expression 
associated significant differences in CRC and GC patient survival. In lymph 
node-positive (Dukes C/stage III) rectal cancer, patients with both strong and 
negative UCHL5 tumor expression exhibited increased survival (p = 0.012) (III: 
Figure 3). In gastric cancer, positive UCHL5 tumor expression-linked increased 
survival were seen in patients with small tumors (<5 cm, p = 0.025), stage I-II of 
the disease (p = 0.001) and those 66 years or older (p = 0.037) (IV: Figure 2). 
High UCHL5 expression has previously been linked to decreased survival and 
cancer recurrence in hepatocellular carcinoma, esophageal squamous cell 
carcinoma and epithelial ovarian cancer [303,309,310]. This is in direct contrast 
with our results, where high or positive UCHL5 expression was found to 
associate with better prognosis in PDAC, and subgroups of CRC and GC patients. 
This could be due in part to differences in the methods used (Western blot; 
[303,310]) and analysis methods. Most importantly, as demonstrated earlier, 
UCHL5 displays a high-degree of tissue-specificity regarding its expression, 
which could also explain the observed difference. 
 
2.2.1. UCHL5 tumor expression association with cancer stage 
 
Further, increased CSS associated with positive UCHL5 tumor expression 
appeared to correlate with stage in all three studied cancer types. In PDAC and 
79 
 
CRC, patients with more serious stage of the disease (Dukes C/stage III in CRC; 
stage IIB-III in PDAC) and high or positive UCHL5 expression appeared to have 
better survival, whereas in gastric cancer patients with lower stage of the disease 
and positive UCHL5 expression had better prognosis. The 5-year CSS for Dukes 
C/stage III CRC patients with high UCHL5 expression was 100% and for patients 
with negative expression 84.4% (95 CI 49.3%-96.0%) (III: Table 2). In 
comparison, for patients with either low or moderate UCHL5 expression, the 5-
year CSS was only 42.5% (95% CI 27.3-56.8) and 47.6% (95% CI 29.0-64.0), 
respectively (III: Table 2). Further, none of the patients with high UCHL5 
expression had died from rectal cancer even 10 years after surgery (III: Table 
1). However, it should be noted that in this subgroup of Dukes C/stage III rectal 
cancer, only 7 patients originally exhibited high UCHL5 tumor expression (III: 
Table 2). 
 
In regional (stages IIB-III) PDAC, 2-year CSS in patients with positive nuclear 
UCHL5 tumor expression was 56.2% (95% CI 41.4-68.6)), compared to 34.0% 
(95% CI 21.7-46.7) in patients with nuclear UCHL5 negativity (II: Table 2). The 
difference in 5-year CSS for these patients was additionally almost two-fold, with 
19.9% (95% CI 10.2-31.9) for UCHL5 positive and 10.4 (95% CI 3.8-20.8) for 
UCHL5 negative patients, respectively (II: Table 2). In contrast, GC-patients 
with lower (stages I-II) stage of the disease and with positive cytoplasmic 
UCHL5 tumor expression had 5-year CSS of 77.2% (95% CI 69.2-83.4), 
compared to 59.0% (95% CI 41.3-73.0) in patients with no cytoplasmic UCHL5 
tumor expression (IV: Table 2). This may reflect the tissue-specificity that 
UCHL5 displays in its expression (II-IV: Figure 1), and in its varied role in 
modulating normal cell functions, including proteasome activity (I: Figure 7B 
and 7C, Supplementary Figure 7). The observation that GC patients with small 
(<5 cm) tumor size and high UCHL5 expression have better prognosis might be 
linked with the increased survival seen in patients with positive UCHL5 
expression and lower (stage I-II) stage of the disease (IV: Figure 2B and 2C). 
There is doubtless a high degree of overlap between these two gastric cancer 
patient subgroups, as patients with lower disease stage also tend to have 
predominantly small tumors. Further, it has been established that UCHL5 and 
Rpn13 together are necessary for cell-cycle progression [238]. It is possible that 
low UCHL5 tumor expression inhibits proliferation in tumor cells, resulting in 




2.2.2. UCHL5 tumor expression association with patient age 
 
Age seemed to be another important factor in the UCHL5 tumor expression-
associated survival benefit in both PDAC and GC. Older patients with positive 
UCHL5 expression had better prognosis in comparison to UCHL5 negative 
patients in these two cancer types (II: Figure 3B and III: Figure 2B). Many 
studies have shown reduced proteasome activity in elderly patients, and a decline 
in proteostasis is one of the hallmarks of aging [255]. However, there is still a 
lack of consensus if this concerns all tissues, and both Ub-dependent and Ub-
independent proteasomal degradation [285]. Yet, assuming reduced proteasome-
associated proteolytic capability in older patients, the increased UCHL5 levels 
may inhibit the proteasome in increasing amounts, thereby promoting apoptosis 
of cancer cells. 
 
 
3. The potential roles of UCHL5 in association with its binding partners and 
a summary of the results 
 
The key points of the results are summarized in Figure 5. Both UCHL5 and 
UBH-4 have a significant role in proteasome modulation, and a clear effect on 
certain lifehistory traits, e.g. patient survival in cancer, and lifespan in C. elegans. 
Across the three studied cancer types, a clear survival benefit was observed in 
patients with positive or high UCHL5 expression. However, the effect of UCHL5 
might not be linked only, or possibly at all, with its association with the 
proteasome. As the 19S Rpn13 subunit is required for UCHL5 binding, all free 
20S CPs lack UCHL5. Some studies suggest a high degree of free 20S in cells, 
particularly in response to stress [145]. In addition, not all conventional 
proteasomes contain Rpn13 [233], and it is possible Rpn13 is in only one of the 
19S of a double-capped (RP-CP-RP) proteasome [593]. One study showed that 
approximately 60% of neuronal proteasomes in rats contained Rpn13 [594]. 
Human Rpn13 was also present in sub-stoichiometric amounts in purified 
proteasomes in two other studies [595,596]. Further, levels of Rpn13 and UCHL5 
are decreased in response to nutrient deprivation [597], which is often a 
characteristic of tumor cells [338]. Increased inflammation of the tumor site and 
the surrounding stroma is another hallmark of cancer [338], inducing the 
expression of the immunoproteasome, which prefers to associate with PA28ab 
activator instead of 19S [67,81]. Importantly, PA28 does not provide a binding 
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site for UCHL5. However, this does not exclude the possibility of hybrid 
proteasomes, capped at one end with a 19S accessible for UCHL5. In addition, 
Rpn13 is found overexpressed in colorectal cancer [598], gastric cancer [599], 
ovarian cancers and acute leukemia [600], potentially providing more available 





Figure 5. Summary of the results. The top hemisphere relates to 




If the UCHL5-associated survival benefit is not linked with the proteasome, then 
it is possible that it stems from the association of UCHL5 with its other binding 
partners. UCHL5 is also a subunit of the chromatin remodeling complex INO80 
[601,602], which belongs to the Sucrose Non-Fermenting 2 (SNF2) ATPase 
family [603]. Although the role of UCHL5 in the context of the INO80 complex 
is not well known, the complex has genome-wide significance in controlling 
chromatin structure and activity [604,605]. INO80 is involved in nucleosome 
turnover [606] and sliding [607], recruiting UCHL5 to the site [608]. HeLa 
INO80 complexes exhibit a high degree of UCHL5 association, and it has been 
suggested that UCHL5-free proteasomes are recruited to INO80 for target protein 
degradation on the chromatin through UCHL5 [235]. In PDAC, positive nuclear 
UCHL5 expression was an important factor in patient prognosis. However, the 
proteasome is found in both the nucleus and the cytoplasm. Therefore, UCHL5 
expression observed in the nucleus is not enough to determine whether UCHL5 
associated with INO80 or the proteasome in this instance. In the light of strong 
cytoplasmic UCHL5 expression present in CRC and GC, it seems unlikely that 
the UCHL5-associated survival benefit is linked solely to INO80. Finally, it 
should be noted that UCHL5 may function only as a surrogate marker, its 
expression following that of some yet unidentified factor(s), which in reality 
convey the survival benefit observed in our research. However, because UCHL5 
displayed tissue-specific prognostic relevance in several cancer types, and 
because UCHL5 inhibition increases degradation of proteotoxic proteins in 





CONCLUSIONS AND FUTURE PROSPECTS 
 
In C. elegans, reduced IIS was associated with increased UPS activity in both the 
intestine and body-wall muscle cells. The DUB UBH-4 was demonstrated to 
modulate proteasome activity in tissue-specific manner with several 
complementing in vivo and biochemical assays. Further, the IIS downstream 
effector DAF-16/FOXO transcription factor was found to negatively regulate 
UBH-4 expression in the C. elegans intestine. Knockdown of mammalian uchl5 
also increased proteasome activity in cancer cells, prompting degradation of 
proteotoxic proteins. Taken together, it appears that at least a part of the increase 
in proteasome activity present under conditions of reduced IIS is mediated 
through the released inhibition of UBH-4 on the proteasome. However, other 
factor(s) are involved in mediating the effect of IIS on UPS activity, based on the 
tissue-specific responses caused by reduced IIS in C. elegans. As seen in the 
variable degradation of our UPS activity reporter in daf-16 mutants in body-wall 
muscle cells, different DAF-16 isoforms mediate specific responses, and further 
IIS effector(s) remain to be identified. Other aging-signaling pathways may also 
regulate the UPS, and it would be interesting to study their potential role in 
modulating the proteasome. However, whatever details will be in uncovered in 
the future, the role of IIS in regulating proteostasis through UPS activity is 
important. 
 
In a set of clinical studies using patient tumor samples, the human orthologue of 
UBH-4, UCHL5, was shown to have relevant prognostic value in three 
gastrointestinal cancers (rectal cancer, gastric cancer and pancreatic ductal 
adenocarcinoma). Significant survival differences were present in several patient 
subgroups; most prominently in the increased survival exhibited by lymph-node-
positive (Dukes C/stage III) rectal cancer patients with high UCHL5 expression. 
Based on our results, UCHL5 is a promising prognostic marker for these cancer 
types, but more study is required to determine its clinical relevance, including 
possible potential as a therapeutic target. Several inhibitors are in development 
for targeting of DUBs in therapy, including proteasome-associated DUBs like 
UCHL5, with high hopes for less severe side-effects and other related adverse 
issues than are associated with conventional proteasome inhibitors. The 
validation of the prognostic potential of UCHL5 in gastrointestinal cancers is 
vital, especially if it is to be developed for use in clinical praxis. Corroborating 
our results in additional and especially international patient cohorts would be an 
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obvious next step to continue this project. Extension of studies to other cancer 
types could also provide interesting results, and further our understanding of the 
tissue-specific functions of UCHL5. At the same time, research into the 
molecular mechanisms causing the increased survival associated with UCHL5 
expression are equally essential; for example, studying different processes 
associated with neoplastic formation and cancer progress in patent-derived tumor 
tissue organoid models, as mediated by UCHL5. 
 
In addition, the significance of UCHL5 association with its other binding 
partners, including the INO80 chromatin remodeling complex, the TGF-b 
inhibitory SMAD7-SMURF2 complex, and possibly other yet unidentified 
factors remain unclear, also in the context of the UCHL5 mediated survival 
benefit. It should also be noted that several different UCHL5 isoforms are 
expressed by mammalian cells, and little is known about the prospective 
differences in their tissue-specific expression or function. Further studies are 
required to fully understand UCHL5 association and functionality in these 
different settings, and perhaps even cellular compartments. In conclusion, the 
specifics of the modulation of proteasome function, both in aging tissues and 
during different disease conditions, deserve more scientific attention. The results 
presented in this thesis may offer potential prognostic value for clinical use and 
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APPENDIX 1A. TNM staging of colorectal cancer after American Joint 
Committee on Cancer (AJCC), 7th edition. 
Stage T N M Dukes’ ACPS 
0 Tis N0 M0 - - 
I T1 N0 M0 
A A  T2 N0 M0 
IIA T3 N0 M0 
B B IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA 
T1-T2 N1/N1c M0 
C C 
T1 N2a M0 
IIIB 
T3-T4a N1/N1c M0 
T2-T3 N2a M0 
T1-T2 N2b M0 
IIIC 
T4a N2a M0 
T3-T4a N2b M0 
T4b N1-N2 M0 
IVA Any T Any N M1a - 
D 
IVB Any T Any N M1b - 
ACPS is the modified Dukes’ staging (Australian Clinio-Pathological 






APPENDIX 1B. T, N and M definitions in colorectal cancer. 
 Primary tumor (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1  Tumor invades submucosa 
T2  Tumor invades muscularis propria 
T3  Tumor invades through the muscularis propria into the   pericolorectal tissues 
T4a  Tumor penetrates to the surface of the visceral peritoneum 
T4b  Tumor directly invades or is adherent to other organs or   structures 
 Regional lymph nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in 1-3 regional lymph nodes 
N1a  Metastasis in 1 regional lymph node 
N1b  Metastasis in 2-3 regional lymph nodes 
N1c  Tumor deposit(s) in the subserosa, mesentery, or  
 nonperitonealized pericolic or perirectal tissues without  
 regional nodal metastasis  
N2  Metastasis in 4 or more lymph nodes 
N2a  Metastasis in 4-6 regional lymph nodes 
N2b  Metastasis in 7 or more regional lymph nodes 
 Distant metastasis (M) 
M0  No distant metastasis 
M1  Distant metastasis 
M1a  Metastasis confined to 1 organ or site (eg, liver, lung, ovary,   nonregional node) 
M1b  Metastases in more than 1 organ/site or the peritoneum 
Reproduced from: http://emedicine.medscape.com/article/2006674-overview 
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APPENDIX 2A. TNM staging of gastric cancer after American Joint Committee 
on Cancer (AJCC), 7th edition. 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB 
T2 N0 M0 
T1 N1 M0 
IIA 
T3 N0 M0 
T2 N1 M0 
T1 N2 M0 
IIB 
T4a N0 M0 
T3 N1 M0 
T2 N2 M0 
T1 N3 M0 
IIIA 
T4a N1 M0 
T3 N2 M0 
T2 N3 M0 
IIIB 
T4b N0 M0 
T4b N1 M0 
T4a N2 M0 
T3 N3 M0 
IIIC 
T4b N2 M0 
T4b N3 M0 
T4a N3 M0 







APPENDIX 2B. T, N and M definitions in gastric cancer. 
 Primary tumor (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ: intraepithelial tumor without invasion of the   lamina propria 
T1  Tumor invades lamina propria, muscularis mucosae, or   submucosa 
T1a  Tumor invades lamina propria or muscularis mucosae 
T1b  Tumor invades submucosa 
T2  Tumor invades muscularis propria 
T3  Tumor penetrates subserosal connective tissue without  
 invasion of visceral peritoneum or adjacent structures 
T4  Tumor invades serosa (visceral peritoneum) or adjacent   structures 
T4a  Tumor invades serosa (visceral peritoneum) 
T4b  Tumor invades adjacent structures 
 Regional lymph nodes (N) 
NX  Regional lymph node(s) cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in 1-2 regional lymph nodes 
N2  Metastasis in 3-6 regional lymph nodes 
N3  Metastasis in seven or more regional lymph nodes 
N3a  Metastasis in 7-15 regional lymph nodes 
N3b  Metastasis in 16 or more regional lymph nodes 
 Distant metastasis (M) 
M0  No distant metastasis 
M1  Distant metastasis 




APPENDIX 3A. TNM staging of pancreatic ductal adenocarcinoma after 
American Joint Committee on Cancer (AJCC), 7th edition. 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB 
T1 N1 M0 
T2 N1 M0 
T3 N1 M0 
III T4 Any N M0 







APPENDIX 3B. TNM definitions in pancreatic ductal adenocarcinoma. 
Primary tumor (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ 
T1  Tumor limited to the pancreas, ≤2 cm in greatest dimension 
T2  Tumor limited to the pancreas, >2 cm in greatest dimension 
T3  Tumor extends beyond the pancreas but without involvement  
 of the celiac axis or the superior mesenteric artery 
T4  Tumor involves the celiac axis or the superior mesenteric 
artery (unresectable primary tumor) 
 Regional lymph nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastasis 
 Distant metastasis (M) 
M0  No distant metastasis 
M1  Distant metastasis 
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